US20100221273A1 - Treatment of viral infections - Google Patents
Treatment of viral infections Download PDFInfo
- Publication number
- US20100221273A1 US20100221273A1 US12/702,919 US70291910A US2010221273A1 US 20100221273 A1 US20100221273 A1 US 20100221273A1 US 70291910 A US70291910 A US 70291910A US 2010221273 A1 US2010221273 A1 US 2010221273A1
- Authority
- US
- United States
- Prior art keywords
- seq
- derivative
- polypeptide
- peptide
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 13
- 230000009385 viral infection Effects 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 308
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 188
- 229920001184 polypeptide Polymers 0.000 claims abstract description 86
- 150000001413 amino acids Chemical class 0.000 claims abstract description 48
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 65
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 229940024606 amino acid Drugs 0.000 claims description 44
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108010043958 Peptoids Proteins 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 101710145752 Serine recombinase gin Proteins 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 56
- 108020004707 nucleic acids Proteins 0.000 description 53
- 102000039446 nucleic acids Human genes 0.000 description 53
- 241000700605 Viruses Species 0.000 description 36
- 230000000840 anti-viral effect Effects 0.000 description 36
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 241000725303 Human immunodeficiency virus Species 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 18
- 101150037123 APOE gene Proteins 0.000 description 13
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 13
- 235000005772 leucine Nutrition 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 102000007592 Apolipoproteins Human genes 0.000 description 8
- 108010071619 Apolipoproteins Proteins 0.000 description 8
- 239000003443 antiviral agent Substances 0.000 description 8
- 150000002614 leucines Chemical group 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 230000036436 anti-hiv Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- -1 gangcylovir Chemical compound 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000234283 Galanthus nivalis Species 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100437782 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BOI1 gene Proteins 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000002962 plaque-reduction assay Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LVXACIPXSUHNDE-CTNRBZHLSA-N 98805-74-4 Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(O)C=C1 LVXACIPXSUHNDE-CTNRBZHLSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 102000018619 Apolipoproteins A Human genes 0.000 description 2
- 108010027004 Apolipoproteins A Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000018655 Apolipoproteins C Human genes 0.000 description 1
- 108010027070 Apolipoproteins C Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000323799 Bat Hepatitis B virus Species 0.000 description 1
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000275449 Diplectrum formosum Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 102100034058 Gypsy retrotransposon integrase-like protein 1 Human genes 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000926251 Homo sapiens Gypsy retrotransposon integrase-like protein 1 Proteins 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010023795 VLDL receptor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004619 light microscopy Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to polypeptides, derivatives or analogues thereof, and to nucleic acids encoding the same with anti-viral activity.
- the invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also in methods of treatment.
- Antiviral agents may target one of six stages of the viral replication cycle, these being:
- replication is the target, which is most effectively influenced by conventional antiviral therapies. Attachment of the virus to the cell is however arguably a more attractive target, as the agent does not need to pass into the host cell. However, this remains an area where few successful therapies have been developed.
- Lipoproteins are globular macromolecular complexes present in serum and other extracellular fluids, consisting of lipid and protein, and are involved in the transport of lipid around the body. They have been categorised according to their density, with the main classes being high density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL). Their proteins are referred to as apolipoproteins, and a number of these have been described, including apolipoproteins A, B, C, D, E, F, G, H, and J. In addition, several sub-types of apolipoproteins A, B and C have been documented.
- HDL high density lipoprotein
- LDL low density lipoprotein
- VLDL very low density lipoprotein
- LPs lipid-binding proteins
- lipoproteins e.g. the LDL receptor
- endogenous antiviral agents for example a soluble form of the VLDL receptor is released into culture medium by HeLa cells and inhibits human rhinovirus infection.
- endogenous antiviral agents for example a soluble form of the VLDL receptor is released into culture medium by HeLa cells and inhibits human rhinovirus infection.
- direct binding between certain apolipoproteins and viral proteins has also been reported. For example:
- HSV1 latent herpes simplex virus type 1
- HSV1 and apoE relates to the independent findings that both of these use cellular heparan sulphate proteoglycan (HSPG) molecules as their initial site of binding to cells, before subsequent attachment to secondary receptors, which raises the possibility that competition may occur at these HSPG sites between HSV1 and apoE containing LPs, which could affect viral entry.
- HSPG heparan sulphate proteoglycan
- Apolipoprotein E has been shown to have effects on the immune system (seemingly unrelated to its role in lipid metabolism) including suppression of T lymphocyte proliferation. Interactions between a number of peptides derived from residues 130-169 of apoE with lymphocytes have been examined (Clay et al., Biochemistry, 34: 11142-11151 (1995)). The region consisting of apoE residues 141-149 are predicted to be particularly important. Similar interactions of such peptides have been described in neuronal cell lines.
- WO 94/04177 discloses that administration of particles containing lipid and amphipathic helical peptides allows clearance of toxins produced by microorganisms, and may increase the effectiveness of antibacterial drugs via an effect on bacterial membranes.
- apoA-derived peptide containing particles may be used as antiviral medicines.
- administration of the peptides in particles which is a key component of the disclosed development (whether the particles are formed before administration or endogenously), would result in effective utilisation of any antiviral action of either component of the particle.
- Azuma et al. have reported that peptide derivatives of apoE have a strong antibacterial action, comparable with that of gentamicin (Peptides, 21: 327-330 (2000)). ApoE 133-162 was the most effective, with apoE 134-155 having little effect.
- Example 1 illustrates how the peptide is effective against viruses such as HSV1, HSV2 and HIV. Accordingly, this peptide may be effective when applied to virus directly, or when applied to virus in the presence of cells, and therefore the peptide can be used to inactivate free virus particles long before they reach their target cells.
- a polypeptide, derivative or analogue thereof comprising a tandem repeat of apoE 141-149 of SEQ ID No 2 or a truncation thereof, characterised in that at least one Leucine (L) residue of SEQ ID No. 2 is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one nitrogen atom.
- L Leucine
- tandem repeat of apoE 141-149 of SEQ ID No. 2 we mean the peptide with the amino acid sequence: LRKLRKRLLLRKLRKRLL.
- the tandem repeat is referred to herein as apoE 141-149dp or apoE 141-149r .
- This peptide is also assigned the code GIN 1 or GIN1p (wherein p signifies N terminal protection (e.g. by an acetyl group), and C terminal protection (e.g. by an amide group)).
- a truncation thereof we mean that the 18mer of SEQ ID No. 2 is reduced in size by removal of amino acids.
- the reduction of amino acids may be by removal of residues from the C or N terminal of the peptide or may be by deletion of one or more amino acids from within the core of the peptide (i.e. amino acids 2-17 of SEQ ID No. 2).
- derivative or analogue thereof we mean that the amino acids residues are replaced by residues (whether natural amino acids, non-natural amino acids or amino acid mimics) with similar side chains or peptide backbone properties. Additionally the terminals of such peptides may be protected by N and C-terminal protecting groups with similar properties to acetyl or amide groups.
- the inventor has identified that Tryptophan (W), Arginine (R) or Lysine (K) may be substituted for Leucine in apoE 141-149 tandem repeats and that such peptides have surprising antiviral activity.
- the inventor appreciated that these amino acids had side chains comprising at least 4 carbons and also containing a nitrogen atom. Accordingly it is preferred that the amino acid used to replace the leucine is Tryptophan (W), Arginine (R) or Lysine (K) or derivatives thereof in the peptide according to the first aspect of the invention.
- peptides in which at least one L has been substituted with a W have particular antiviral activity. It is therefore most preferred that peptides according to the first aspect of the invention comprise a polypeptide, derivative or analogue thereof comprising a tandem repeat of apoE 141-149 of SEQ ID No 2 or a truncation thereof, characterised in that at least one Leucine (L) residue of SEQ ID No. 2 is replaced by a Tryptophan (W).
- L Leucine
- W Tryptophan
- SEQ ID No 2 may be manipulated according to the first aspect of the invention with a number of different substitutions and deletions to make peptides with antiviral activity.
- the polypeptide according to the first aspect of the invention has at least two W, R or K substitutions, and more preferably three or more W, R or K substitutions.
- At least one further amino acid preferably at least one further leucine residue
- Y Tyrosine
- C Cysteine
- M Methionine
- F Phenylalanine
- I Isoleucine
- Q Glutamine
- H Histidine
- the substituted polypeptide may comprise 18 amino acids (or derivatives thereof) and thereby correspond to the full length of SEQ ID No. 2.
- truncated peptides based on SEQ ID No.2 also have efficacy as antiviral agents.
- preferred peptides or derivatives thereof may have less than 18 amino acids.
- some peptides according to the first aspect of the invention may be 17, 16, 15, 14, 13, 12, 11, 10 or less amino acids in length.
- Peptides, and derivatives thereof, according to the present invention preferably have an efficacy for inhibiting viral growth such that their IC50 value is 30 ⁇ M or less. It is preferred that the IC50 value is 20 ⁇ M or less and more preferred that the IC50 value is 10 ⁇ M or less.
- Preferred peptides have similar IC 50 values between viral species. For instance preferred peptides have similar IC 50 values for inhibiting HSV1, HSV2 and HIV growth.
- modified amino acids may be substituted into the tandem repeat of apoE 141-149 with a number of amino acid variants that may be known to those skilled in the art Such peptides will still have antiviral activity provided that the modification does no significantly alter its chemical characteristics.
- hydrogens on the side chain amines of R or K may be replaced with methylene groups (—NH 2 ⁇ —NH(Me) or —N(Me) 2 ).
- Preferred peptides according to the first aspect of the invention have the amino acids sequence:
- WRKWRKRWWWRKWRKRWW (SEQ ID No. 3). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Tryptophan residues. This peptide is designated GIN 7 when referred to herein.
- b WRKWRKRWRKWRKR (SEQ ID No. 4). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Tryptophan residues and truncated by the excision of amino acids 9, 10, 17 and 18. This peptide is designated GIN 32 when referred to herein.
- WRKWRKRWWLRKLRKRLL (SEQ ID No. 5).
- This peptide corresponds to the full length tandem repeat with a subset of Leucines substituted for tryptophan residues.
- This peptide is designated GIN 34 when referred to herein.
- (d) WRKWRKRWWRKWRKRWW (SEQ ID No. 52). This peptide corresponds to SEQ ID No. 3 with the W residue at position 9 deleted. This peptide is designated MU 58 when referred to herein.
- This peptide is designated MU 59 when referred to herein.
- This peptide is designated MU 68 when referred to herein.
- LRKLRKRLLWRKWRKRWW SEQ ID No. 57. This peptide corresponds to SEQ ID No. 2 with the L residues at positions 10, 13, 17 and 18 substituted with W residues.
- This peptide is designated MU 111 when referred to herein.
- LRKLRKRLLLRKLRKRWW SEQ ID No. 58. This peptide corresponds to SEQ ID No. 2 with the L residues at positions 17 and 18 substituted with W residues.
- This peptide is designated MU 112 when referred to herein.
- This peptide is designated MU 115 when referred to herein.
- (n) WRKWRKFFFRKWRKRWW (SEQ ID No. 62).
- This peptide corresponds to SEQ ID No. 3 with the W residues at positions 8, 9 and 10 substituted with F residues and the R residue at position 7 deleted.
- This peptide is designated MU 116 when referred to herein.
- (0) WRKWRKRWWFRKFRKRFF SEQ ID No. 63
- This peptide corresponds to SEQ ID No. 3 with the W residues at positions 10, 13, 17 and 18 substituted with F residues.
- This peptide is designated MU 117 when referred to herein.
- peptides may be employed according to the invention that comprise more than just a simple dimer tandem repeat of ApoE 141-149 or a truncation thereof.
- peptides comprising a trimer or greater number of repeats may be employed as antiviral agents.
- antiviral peptides may be synthesised that comprise a peptide as defined above to which further amino acids have been added.
- one, two, three or more amino acids may be added to the C or N terminals of a peptide derived from SEQ ID No. 2.
- the peptide may comprise a tandem repeat of a peptide that is larger than the nine amino acids of SEQ ID No. 1.
- Such peptides may have amino acids added to the N terminal, C terminal and/or between the 9 th and 10 th amino acids of SEQ ID No. 2. It is most preferred that the amino acid is added to C terminal and also between the 9 th and 10 th amino acids of SEQ ID No. 2.
- peptides may then be modified as described above for peptides derived from SEQ ID No. 2.
- SEQ ID No. 66 represents another preferred peptide according to the present invention.
- This peptide corresponds to the full length tandem repeat of ApoE 141-150 (i.e. a tandem repeat of LRKLRKRLLR—SEQ ID No. 67) with all Leucines substituted for Tryptophan residues.
- This peptide is designated MU 83 when referred to herein.
- LRKLRKRLLLRKLRKLRK SEQ ID No. 7
- This peptide corresponds to a truncated form of the full length tandem repeat with residues 16, 17 and 18 deleted. This peptide has the advantage that the peptide is shorter than GIN 1 and is therefore cheaper to manufacture. This peptide is designated GIN 4 when referred to herein.
- LRKLRKRLRKLRKR SEQ ID No. 8
- This peptide corresponds to the full length tandem repeat truncated by the excision of amino acids 9, 10, 17 and 18. This peptide is designated GIN 8 when referred to herein.
- LRKLRKLRKLRKLRKLRKLRKLRK SEQ ID No. 9
- This peptide corresponds to a variation of the full length tandem repeat comprising a repeat of the LRK motif. This peptide is designated GIN 9 when referred to herein. Furthermore YRKYRKRYYYRKYRKRYY (SEQ ID No. 6) was found to be effect as an antiviral agent. This peptide corresponds to the full length tandem repeat of apoE 141-149 with all Leucines substituted for Tyrosine residues. This peptide is designated GIN 41 when referred to herein.
- a polypeptide, derivative or analogue thereof according to the first aspect of the invention or a peptide of SEQ ID No. 6, 7, 8 or 9 for use as a medicament According to a second aspect of the invention there is provided a polypeptide, derivative or analogue thereof according to the first aspect of the invention or a peptide of SEQ ID No. 6, 7, 8 or 9 for use as a medicament.
- a polypeptide, derivative or analogue thereof according to the first aspect of the invention or a peptide of SEQ ID No. 6, 7, 8 or 9 for the manufacture of a medicament for treating viral infections.
- polypeptides, derivatives or analogues according to the first aspect of the invention may also be mediated “indirectly” by agents that increase the activity of such polypeptides, derivatives or analogues.
- the present invention provides the first medical use of such agents.
- Agents capable of increasing the biological activity of polypeptides, derivatives or analogues according to the invention may achieve their effect by a number of means. For instance, such agents may increase the expression of such polypeptides, derivatives or analogues. Alternatively (or in addition) such agents may increase the half-life of polypeptides, derivatives or analogues according to the invention in a biological system, for example by decreasing turnover of the polypeptides, derivatives or analogues.
- polypeptides, derivatives or analogues according to the first three aspects of the invention are of utility as antiviral agents.
- the virus may be any virus, and particularly an enveloped virus.
- Preferred viruses are poxviruses, iridoviruses, togaviruses, or toroviruses.
- a more preferred virus is a filovirus, arenavirus, bunyavirus, or a rhabdovirus.
- An even more preferred virus is a paramyxovirus or an orthomyxovirus.
- virus may preferably include a hepadnavirus, coronavirus, flavivirus, or a retrovirus.
- the virus includes a herpesvirus or a lentivirus.
- the virus may be Human Immunodeficiency Virus (HIV), Human herpes simplex virus type 2 (HSV2), or Human herpes simplex virus type 1 (HSV1).
- Polypeptides, derivatives or analogues according to the first, second and third aspects of the invention may be used to treat viral infections as a monotherapy (i.e. use of the compound alone) or in combination with other compounds or treatments used in antiviral therapy (e.g. acyclovir, gangcylovir, ribavirin, interferon, anti-HIV medicaments including nucleoside, nucleotide or non-nucleoside inhibitors of reverse transcriptase, protease inhibitors and fusion inhibitors.)
- a monotherapy i.e. use of the compound alone
- other compounds or treatments used in antiviral therapy e.g. acyclovir, gangcylovir, ribavirin, interferon
- anti-HIV medicaments including nucleoside, nucleotide or non-nucleoside inhibitors of reverse transcriptase, protease inhibitors and fusion inhibitors.
- polypeptides, derivatives or analogues may be used as a prophylactic (to prevent the development of a viral infection) or may be used to treat existing infections.
- Derivatives of polypeptides according to the invention may include derivatives that increase or decrease the polypeptide's half-life in vivo.
- Examples of derivatives capable of increasing the half-life of polypeptides according to the invention include peptoid derivatives of the polypeptides, D-amino acid derivatives of the polypeptides, and peptide-peptoid hybrids.
- Polypeptides according to the invention may be subject to degradation by a number of means (such as protease activity in biological systems). Such degradation may limit the bioavailability of the polypeptides and hence the ability of the polypeptides to achieve their biological function.
- a number of means such as protease activity in biological systems.
- Such degradation may limit the bioavailability of the polypeptides and hence the ability of the polypeptides to achieve their biological function.
- peptide derivatives that have enhanced stability in biological contexts can be designed and produced.
- Such peptide derivatives may have improved bioavailability as a result of increased resistance to protease-mediated degradation.
- a peptide derivative or analogue suitable for use according to the invention is more protease-resistant than the peptide from which it is derived.
- Protease-resistance of a peptide derivative and the peptide from which it is derived may be evaluated by means of well-known protein degradation assays. The relative values of protease resistance for the peptide derivative and peptide may then be compared.
- Peptoid derivatives of the peptides of the invention may be readily designed from knowledge of the structure of the peptide according to the first aspect of the invention. Commercially available software may be used to develop peptoid derivatives according to well-established protocols.
- Retropeptoids (in which all amino acids are replaced by peptoid residues in reversed order) are also able to mimic antiviral peptides derived from apolipoproteins.
- a retropeptoid is expected to bind in the opposite direction in the ligand-binding groove, as compared to a peptide or peptoid-peptide hybrid containing one peptoid residue.
- the side chains of the peptoid residues are able point in the same direction as the side chains in the original peptide.
- a further embodiment of a modified form of polypeptides according to the invention comprises D-amino acid forms of the polypeptides.
- the preparation of peptides using D-amino acids rather than L-amino acids greatly decreases any unwanted breakdown of such an agent by normal metabolic processes, decreasing the amounts of agent which need to be administered, along with the frequency of its administration.
- polypeptides, analogues, or derivatives of the invention represent products that may advantageously be expressed by biological cells.
- the present invention also provides, in a fifth aspect, a nucleic acid sequence encoding a polypeptide, derivative or analogue according to the first aspect of the invention.
- the nucleic acids encoding apoE 141-149 has the DNA sequence cttcgtaaacttcgtaaacgtcttctt (SEQ ID. No. 10) whereas GIN 1 has the sequence cttcgtaaacttcgtaaacgtcttcttcttcgtaaacttcgtaaacgtcttcttttt (SEQ ID. No. 11).
- Preferred nucleic acids according to the fifth aspect of the invention encode the peptides identified herein as GIN 4, 7, 8, 9, 32, 34 and 41 have the following respective sequences:
- nucleic acid sequence of other preferred peptides according to the present invention may be readily generated.
- nucleic acid sequence in accordance with the fifth aspect of the invention may vary from the naturally occurring ApoE gene providing a codon encodes a polypeptide, derivative or analogue thereof in accordance with the first aspect of the invention.
- polypeptides, derivatives and analogues according to the invention represent favourable agents to be administered by techniques involving cellular expression of nucleic acid sequences encoding such molecules. Such methods of cellular expression are particularly suitable for medical use in which the therapeutic effects of the polypeptides, derivatives and analogues are required over a prolonged period.
- nucleic acid sequence according to the fifth aspect of the invention for use as a medicament.
- the nucleic acid may preferably be an isolated or purified nucleic acid sequence.
- the nucleic acid sequence may preferably be a DNA sequence.
- the nucleic acid sequence may further comprise elements capable of controlling and/or enhancing its expression.
- the nucleic acid molecule may be contained within a suitable vector to form a recombinant vector.
- the vector may for example be a plasmid, cosmid or phage. Such recombinant vectors are highly useful in the delivery systems of the invention for transforming cells with the nucleic acid molecule.
- Recombinant vectors may also include other functional elements.
- recombinant vectors can be designed such that the vector will autonomously replicate in the cell. In this case elements that induce nucleic acid replication may be required in the recombinant vector.
- the recombinant vector may be designed such that the vector and recombinant nucleic acid molecule integrates into the genome of a cell. In this case nucleic acid sequences, which favour targeted integration (e.g. by homologous recombination) are desirable.
- Recombinant vectors may also have DNA coding for genes that may be used as selectable markers in the cloning process.
- the recombinant vector may also further comprise a promoter or regulator to control expression of the gene as required.
- the nucleic acid molecule may (but not necessarily) be one, which becomes incorporated in the DNA of cells of the subject being treated. Undifferentiated cells may be stably transformed leading to the production of genetically modified daughter cells (in which case regulation of expression in the subject may be required e.g. with specific transcription factors or gene activators). Alternatively, the delivery system may be designed to favour unstable or transient transformation of differentiated cells in the subject being treated. When this is the case, regulation of expression may be less important because expression of the DNA molecule will stop when the transformed cells die or stop expressing the protein (ideally when the required therapeutic effect has been achieved).
- the delivery system may provide the nucleic acid molecule to the subject without it being incorporated in a vector.
- the nucleic acid molecule may be incorporated within a liposome or virus particle.
- a “naked” nucleic acid molecule may be inserted into a subject's cells by a suitable means e.g. direct endocytotic uptake.
- the nucleic acid molecule may be transferred to the cells of a subject to be treated by transfection, infection, microinjection, cell fusion, protoplast fusion or ballistic bombardment.
- transfer may be by ballistic transfection with coated gold particles, liposomes containing the nucleic acid molecule, viral vectors (e.g. adenovirus) and means of providing direct nucleic acid uptake (e.g. endocytosis) by application of the nucleic acid molecule directly.
- polypeptides, agents, nucleic acids or derivatives according to the present invention may be used in a monotherapy (i.e. use of polypeptides, agents, nucleic acids or derivatives according to the invention alone to prevent and/or treat a viral infection).
- polypeptides, agents, nucleic acids or derivatives according to the invention may be used as an adjunct, or in combination with, known therapies.
- compositions having a number of different forms depending, in particular on the manner in which the composition is to be used.
- the composition may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle, transdermal patch, liposome or any other suitable form that may be administered to a person or animal.
- vehicle of the composition of the invention should be one which is well tolerated by the subject to whom it is given, and is preferably adapted to enable delivery of the polypeptides, agents, nucleic acids or derivatives to the target tissue.
- compositions comprising polypeptides, agents, nucleic acids or derivatives according to the invention may be used in a number of ways.
- oral administration may be required in which case the compound may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid.
- the composition may be administered by injection into the blood stream. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion).
- the compounds may be administered by inhalation (e.g. intranasally).
- compositions may be formulated for topical use. For instance, ointments may be applied to the skin, areas in and around the mouth or genitals to treat specific viral infections. Topical application to the skin is particularly useful for treating viral infections of the skin or as a means of transdermal delivery to other tissues. Intravaginal administration is effective for treating sexually transmitted diseases (including AIDS).
- Polypeptides, agents, nucleic acids or derivatives may also be incorporated within a slow or delayed release device. Such devices may, for example, be inserted on or under the skin, and the compound may be released over weeks or even months. Such devices may be particularly advantageous when long term treatment with a polypeptide, agent, nucleic acid or derivative according to the invention is required and which would normally require frequent administration (e.g. at least daily injection).
- the amount of a polypeptide, agent, nucleic acid or derivative that is required is determined by its biological activity and bioavailability which in turn depends on the mode of administration, the physicochemical properties of the polypeptide, agent, nucleic acid or derivative employed and whether the polypeptide, agent, nucleic acid or derivative is being used as a monotherapy or in a combined therapy.
- the frequency of administration will also be influenced by the above-mentioned factors and particularly the half-life of the polypeptide, agent, nucleic acid or derivative within the subject being treated.
- Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular polypeptide, agent, nucleic acid or derivative in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
- a daily dose of between 0.01 ⁇ g/kg of body weight and 0.5 g/kg of body weight of polypeptides, agents, nucleic acids or derivatives according to the invention may be used for the prevention and/or treatment of a viral infection, depending upon which specific polypeptide, agent, nucleic acid or derivative is used. More preferably, the daily dose is between 0.01 mg/kg of body weight and 200 mg/kg of body weight, and most preferably, between approximately 1 mg/kg and 100 mg/kg.
- Known procedures such as those conventionally employed by the pharmaceutical industry (e.g. in vivo experimentation, clinical trials, etc.), may be used to establish specific formulations of polypeptides, agents, nucleic acids or derivatives according to the invention and precise therapeutic regimes (such as daily doses of the polypeptides, agents, nucleic acids or derivatives and the frequency of administration).
- Daily doses may be given as a single administration (e.g. a single daily injection).
- the polypeptide, agent, nucleic acid or derivative used may require administration twice or more times during a day.
- polypeptides, agents, nucleic acids or derivatives according to the invention may be administered as two (or more depending upon the severity of the condition) daily doses of between 25 mg and 7000 mg (i.e. assuming a body weight of 70 kg).
- a patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3 or 4 hourly intervals thereafter.
- a slow release device may be used to provide optimal doses to a patient without the need to administer repeated doses.
- This invention provides a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide, agent, nucleic acid or derivative according to the invention and optionally a pharmaceutically acceptable vehicle.
- the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 800 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 500 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 250 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.1 mg to about 60 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.1 mg to about 20 mg.
- This invention provides a process for making a pharmaceutical composition
- a pharmaceutical composition comprising combining a therapeutically effective amount of a polypeptide, agent, nucleic acid or derivative according to the invention and a pharmaceutically acceptable vehicle.
- a “therapeutically effective amount” is any amount of a polypeptide, agent, nucleic acid or derivative according to the first aspect of the invention which, when administered to a subject provides prevention and/or treatment of a viral infection.
- a “subject” is a vertebrate, mammal, domestic animal or human being.
- a “pharmaceutically acceptable vehicle” as referred to herein is any physiological vehicle known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.
- the pharmaceutical vehicle is a liquid and the pharmaceutical composition is in the form of a solution.
- the pharmaceutically acceptable vehicle is a solid and the composition is in the form of a powder or tablet.
- the pharmaceutical vehicle is a gel and the composition is in the form of a cream or the like.
- a solid vehicle can include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
- the vehicle is a finely divided solid that is in admixture with the finely divided active polypeptide, agent, nucleic acid or derivative.
- the active polypeptide, agent, nucleic acid or derivative is mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain up to 99% of the active polypeptide, agent, nucleic acid or derivative.
- Suitable solid vehicles include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
- the active polypeptide, agent, nucleic acid or derivative can be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- the liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators.
- suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, e.g.
- cellulose derivatives preferably sodium carboxymethyl cellulose solution
- alcohols including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil).
- the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration.
- the liquid vehicle for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and particularly subcutaneous, intracerebral or intracerebroventricular injection.
- the polypeptide, agent, nucleic acid or derivative may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
- Vehicles are intended to include necessary and inert binders, suspending agents, lubricants, flavourants, sweeteners, preservatives, dyes, and coatings.
- Polypeptides, agents, nucleic acids or derivatives according to the invention can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- solutes or suspending agents for example, enough saline or glucose to make the solution isotonic
- bile salts for example, enough saline or glucose to make the solution isotonic
- acacia gelatin
- sorbitan monoleate sorbitan monoleate
- polysorbate 80 oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide
- compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
- forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- FIG. 1 shows the effect of apoE 141-149dp and apoE 263-286 on HSV1 infectivity. (points are derived from the average of up to four values) as described in Example 1;
- FIG. 2 shows the effect of apoE 141-149dp or apoE 263-286 on HSV2 infectivity (points are derived from the average of up to four values) as described in Example 1;
- FIG. 3 illustrates inhibition of HIV-1 p24 production, as measured by ELISA, by apoE 141-149r , and apoE 263-286 in acutely infected U937 cells (values are the average of three experiments) as described in Example 1 (ApoE 141-149dp was significantly active against HIV (ANOVA, p ⁇ 0.001), whereas the activity of apoE 263-286 against HIV did not reach significance (ANOVA; 0.06 ⁇ p ⁇ 0.62));
- FIG. 4 illustrates the effect of 4 peptides (GIN1, 1p, 2 and 3) on HSV1 infectivity as described in Example 2;
- FIG. 5 illustrates the effect of 4 peptides (GIN 4-7) on HSV1 infectivity as described in Example 2;
- FIG. 6 illustrates the effect of 4 peptides (GIN 8-11) on HSV1 infectivity as described in Example 2;
- FIG. 7 compares and illustrates the effect of peptides GIN 7, GIN 32, GIN 34, and GIN 1p on HSV1 infectivity as described in Example 2;
- FIG. 8 illustrates the anti-HIV action of peptide GIN7 against HIV isolate SF162, grown in NP-2 glioma cells overexpressing CCR5 co-receptors as described in Example 4;
- FIG. 9 shows typical mass spectrometry data for GIN7 and illustrates that the peptide was >95% purity
- FIG. 10 shows typical HPLC data for GIN7 and illustrates that the peptide was >95% purity.
- FIG. 1 and table 1 show typical results for the test for anti-HSV1 activity.
- the assay involved treating confluent Vero cells in 24-well plates with medium containing virus and varying amounts of peptide for one hour, followed by removal of this inoculum, and addition of viscous ‘overlay’ medium, containing 0.2% high viscosity carboxymethylcellulose.
- the overlay medium only allows infection of those cells immediately adjacent to an infected cell. After 2 days incubation and then fixation and staining, small patches of infected cells (or ‘plaques’) are visible, which are counted. Each of these corresponds to the infection of a single cell during the one hour inoculation.
- ApoE 141-149dp produced a 40% reduction in plaque number at a concentration of around 20 ⁇ M. Note the peptide was only present in the experimental system for 1 hour.
- FIG. 2 and table 2 show typical results for the test for anti-HSV2 activity.
- the assay was carried out as for the anti-HSV1 assay, except Hep-2 cells were used rather than Vero cells.
- ApoE 141-149dp produced a 50% reduction in plaque number at a concentration of around 20 ⁇ M. Again note that the peptide was only present in the experimental system for 1 hour.
- FIG. 3 and table 3 show typical results for the test for anti-HIV activity.
- the assay was carried out by incubating HIV infected U937 cells in the presence of various levels of peptide for 7 days, followed by assay for levels of the HIV protein p24 in the cells using an Enzyme Linked Immunoabsorbant Assay (ELISA) technique.
- ELISA Enzyme Linked Immunoabsorbant Assay
- ApoE 141-149dp produced a 95% reduction in infectivity at 20 ⁇ M.
- ApoE 263-286 produced a 20% reduction in infectivity at 20 ⁇ M, which did not reach statistical significance.
- African Green Monkey Kidney (Vero) cells were maintained in Eagle's minimum essential medium with Earle's salt (EMEM) and supplemented with 10% foetal calf serum (heat-inactivated), 4 mM L-glutamine, and 1% (v/v) nonessential amino acids, plus penicillin and streptomycin (100 IU/mg and 100 mg/ml, respectively) (maintenance medium referred to as 10% EMEM). The cells were incubated at 37° C. in a humidified atmosphere of air with 5% CO 2 .
- EMEM Eagle's minimum essential medium with Earle's salt
- HSV1 virus Three separate passages of HSV1 virus were prepared by infecting Vero cells, and preparing semi-pure suspensions of virus from tissue culture supernatant and cell lysates, before freezing aliquots of virus at ⁇ 85° C. Viral infectivity was assessed by carrying out plaque assays on serial dilutions of thawed aliquots (expressed in pfu/ml).
- Peptides were obtained in lyophilised form from a commercial supplier (AltaBioscience, University of Birmingham or Advanced Biomedical), and were produced at 5 micromole scale. N-terminals were protected by addition of an acetyl group, and the C-terminals were protected by addition of an amide group.
- Vero cells were seeded at 125,000 cells per well in 10% EMEM, and were incubated overnight resulting in confluent monolayers. Peptides were diluted in 0.5% EMEM to give 2 ⁇ final desired concentration, and 100 ⁇ l aliquots were arranged on 96-well plates in arrangement to be used for 24-well plate; control wells containing normal 0.5% EMEM were also prepared. Virus stocks (p3) were thawed, and diluted in 0.5% EMEM such that there were around 100 pfu in 100 ⁇ l. Each 24-well plate was inoculated separately. Firstly 100 ⁇ l of virus stock was added to the peptide or control medium arranged on a 96-well plate. This was incubated at 37° C.
- Vero cells were seeded in 96-well plates at 30,000 cells per well in 10% EMEM, and were incubated overnight resulting in confluent monolayers.
- GIN peptides were diluted in 0.5% EMEM to give final desired concentration, and 100 ⁇ l aliquots were arranged on separate non-cell containing 96-well plates, prior to taking Vero 96-well plates, removing 10% EMEM, and adding 0.5% EMEM containing peptides. After incubating for 48 hours, 25 ⁇ l of 1.5 mg/ml MTT solution (in 0.5% EMEM) was added per well, and plates returned to incubator for one hour.
- FIG. 4 illustrates that the ApoE 141-149dp (labelled as GIN 1) had good efficacy for reducing HSV1 infectivity.
- a related peptide GIN 1p (GIN 1 with N and C terminal protection) had similar efficacy.
- the inventors tested a number of other related peptides (identified as GIN 2, GIN 3, GIN 4, GIN 5, GIN 6, GIN 10, GIN 11, GIN 12, GIN 13, GIN 14 and GIN 15) and it was found that they had no, or poor, efficacy for reducing viral infectivity.
- FIG. 5 illustrates that the peptide designated GIN 7 had efficacy for reducing HSV-1 infectivity.
- FIG. 6 illustrates that the peptides designated GIN 8 and GIN 9 also had efficacy for reducing HSV-1 infectivity.
- Table 5 and FIG. 4 a illustrate that a number of peptides related or similar to the ApoE 141-149dp peptide (identified as peptides GIN 17-31 in Table 4a) had no, or poor, efficacy for reducing viral infectivity.
- the inventors had rationally designed these molecules in the expectation that they may have anti-HSV1 activity and, based on the data presented in Table 4, a skilled person may have expected such peptides to have similar efficacy to those claimed according to the invention. The fact that these peptides had little effect makes the usefulness of the claimed peptides all the more surprising.
- FIG. 7 compares and illustrates the effect of peptides GIN 7, GIN 32, GIN 34, and GIN 1p on HSV1 infectivity.
- the glioma cell line NP2 over-expressing both CD4 and the appropriate co-receptor (CCR5 or CXCR4) were maintained in DMEM supplemented with 10% FCS. 2 ⁇ 10 4 cells were plated per well of a 48-well plate 24 h prior to infection and grown at 37 C. The cells were then washed, and incubated in DMEM/FCS containing peptide concentrations ranging from 0.1 to 10 micromolar, at 37 C for 30 minutes. 200 focus-forming units of HIV-1 stocks were then added to each well, and the cells incubated at 37 C for a further 2 hours. The cells were then washed twice in PBS and fresh medium replaced.
- the cells were fixed in cold methanol:acetone, and stained in situ for expression of HIV-1 p24 using a monoclonal anti-p24 followed by a secondary anti-mouse beta-galactosidase conjugate. Expression was visualised by X-Gal staining and infectious foci enumerated by light-microscopy.
- FIG. 8 illustrates the anti-HIV action of peptide GIN 7 against HIV isolate SF162, grown in NP-2 glioma cells overexpressing CCR5 co-receptors.
- GIN 1p (apoEdp) had no detectable anti-HIV activity in the one combination of HIV strain and cell type against which this peptide was tested, and at the concentrations used here (up to 10 ⁇ M). This would suggest the W substituted peptides according to the present invention are more potent against HIV than GIN 1p (apoE 141-149dp ).
- Table 7 illustrates that peptides according to the present invention have efficacy for inhibiting the growth of HSV1 (i.e. W, R or K substitution).
- the peptides according to the first aspect of the invention surprisingly have more efficacy than the apoE tandem repeat (GIN 1/MU 10).
- substitution with M, Y, F, I, Q, H or N had some efficacy (comparable with the apoE tandem repeat) and as such further substitutions according to the invention may comprise these amino acids.
- substitution of amino acids with small side chains tends to abolish antiviral activity whereas as amino acids with larger side chains maintain the antiviral effects.
- substitution of L with amino acids as defined by the first aspect of the invention confers surprising antiviral activity.
- LRKLRKRLLLRKLRKRLL 30 MU 10 (GIN 1) 2. LRKLRKRLLLRKLRKRLL 16.5 (no N/C protect) MU 11 74 NRKNRKRNNNRKNRKRNN 27.5 MU 13 75 SRKSRKRSSSRKSRKRSS NA MU 14 76 VRKVRKRVVVRKVRKRVV NA MU 15 77 TRKTRKRTTTRKTRKRTT NA MU 16 64 RRKRRKRRRRRKRRKRRR 7.5 MU 17 78 GRKGRKRGGGRKGRKRGG NA MU 18 65 KRKKRKRKKKRKKRKRKK 7.5 MU 19 79 HRKHRKRHHHRKHRKRHH NA MU 20 80 PRKPRKRPPPRKPRKRPP NA 5.2.2 Testing of Further apoE Derived Peptides.
- the inventor constructed an expanded library of peptides to evaluate what apoE peptide derivatives may have antiviral activity.
- Table 8 illustrates that a number of peptides, which were based on SEQ ID No. 2 but fall outside the definition of peptides according to the first aspect of the invention, had no or poor antiviral activity (e.g. MU 24-46). It is interesting to note that MU 43 and MU 44 correspond to tandem repeats of the murine and bovine equivalents to apoE 141-149 respectively whereas MU 46 corresponds to apoE 141-149 (SEQ ID No. 1).
- Plaque assays were performed. The methodology was as described in previous Examples for HSV1 plaque assays (including usage of Vero cells) except HSV2 clinical isolates (provided by Prof. Anthony Hart of Liverpool University) were employed instead.
- Peptides prepared as described previously were diluted in 50 ⁇ l aliquots and mixed with T-cells (C8166) at 40,000 cells per well.
- HIV-1 111B was added at a multiplicity of infection (MOI) of 0.01, and the mixture incubated for 5 days at 37° C.
- MOI multiplicity of infection
- Syncytia formation was assessed visually using an inverting microscope, and viral gp120 levels in supernatants assessed by a gp120 ELISA using GNA for antigen capture.
- test sample supernatants were added to wells, along with dilutions of infected control samples.
- 50 ⁇ l of human anti-HIV sera was added, and plates incubated overnight.
- 50 ⁇ l of a 1000 ⁇ dilution of anti-human Ig peroxidase conjugate was added, and plates incubated at 37° C. for 90 min.
- 50 ⁇ l peroxidase substrate was added to each well, and plates incubated for 10-30 min. Reaction was stopped with 25 ⁇ l 2M H 2 SO 4 , and A450 measured.
- Example 4 Further tests were conducted to support the data presented in Example 4 illustrating that peptides according to the present invention were effective against HIV as well as both HSV1 and HSV2.
- GIN 32 (SEQ ID No. 4) had an IC 50 of 7.5 ⁇ M for inhibiting HIV-1 growth. The efficacy of this was similar in HSV1, HSV2 and HIV. This confirms that peptides according to the present invention have broad antiviral effects.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates to polypeptides, derivatives or analogues thereof, and to nucleic acids encoding the same with anti-viral activity. The invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also in methods of treatment.
- Antiviral agents may target one of six stages of the viral replication cycle, these being:
- 1. Attachment of the virus to the cell;
- 2. Penetration (or fusion of the viral membrane with the cell membrane);
- 3. Uncoating of the virus;
- 4. Replication of the viral nucleic acids;
- 5. Maturation of progeny virus particles; and
- 6. Release of progeny virus into extracellular fluids.
- Of these six stages, replication (
stage 4 above) is the target, which is most effectively influenced by conventional antiviral therapies. Attachment of the virus to the cell is however arguably a more attractive target, as the agent does not need to pass into the host cell. However, this remains an area where few successful therapies have been developed. - It is therefore one object of the present invention to provide therapeutic agents that modulate viral attachment to cells.
- Lipoproteins (LPs) are globular macromolecular complexes present in serum and other extracellular fluids, consisting of lipid and protein, and are involved in the transport of lipid around the body. They have been categorised according to their density, with the main classes being high density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL). Their proteins are referred to as apolipoproteins, and a number of these have been described, including apolipoproteins A, B, C, D, E, F, G, H, and J. In addition, several sub-types of apolipoproteins A, B and C have been documented.
- Various interactions have been described linking LPs with viruses. These mostly involving binding of viruses to lipoproteins, with this resulting in either diminished viral infectivity, or conversely providing a ‘hitchhiker’ method for the virus to enter cells. Additionally, several viruses make use of cellular receptors for LPs (e.g. the LDL receptor) as a means of entering cells, although these receptors can also be released by cells as endogenous antiviral agents (for example a soluble form of the VLDL receptor is released into culture medium by HeLa cells and inhibits human rhinovirus infection). Furthermore, direct binding between certain apolipoproteins and viral proteins has also been reported. For example:
-
- a. Hepatitis C virus core protein binds to apolipoprotein AII;
- b. Hepatitis B virus surface antigen binds apolipoprotein H; and
- c. Simian immunodeficiency virus (SIV) gp32 protein, and human immunodeficiency virus (HIV) gp41 protein binds to apolipoprotein A1.
- Work conducted in the laboratory of the inventor has shown that the presence of latent herpes simplex virus type 1 (HSV1) in brain and the possession of a particular allele of a specific gene—the APOE-e4 allele of the APOE gene—increases the risk of development of Alzheimer's disease (AD). Taken with the additional finding that APOE-e4 carriers are more likely to suffer from cold sores (which are lesions found after reactivation of HSV1 in the peripheral nervous system), these results suggested that APOE-e4 carriers are more likely to suffer damage from HSV1 infections, and suggests that there may be interactions between apolipoprotein E and certain viruses (although such interactions need not necessarily involve antiviral effects). One possible mode of interaction between HSV1 and apoE relates to the independent findings that both of these use cellular heparan sulphate proteoglycan (HSPG) molecules as their initial site of binding to cells, before subsequent attachment to secondary receptors, which raises the possibility that competition may occur at these HSPG sites between HSV1 and apoE containing LPs, which could affect viral entry.
- Apolipoprotein E has been shown to have effects on the immune system (seemingly unrelated to its role in lipid metabolism) including suppression of T lymphocyte proliferation. Interactions between a number of peptides derived from residues 130-169 of apoE with lymphocytes have been examined (Clay et al., Biochemistry, 34: 11142-11151 (1995)). The region consisting of apoE residues 141-149 are predicted to be particularly important. Similar interactions of such peptides have been described in neuronal cell lines.
- WO 94/04177 discloses that administration of particles containing lipid and amphipathic helical peptides allows clearance of toxins produced by microorganisms, and may increase the effectiveness of antibacterial drugs via an effect on bacterial membranes. However, there is no suggestion that such apoA-derived peptide containing particles may be used as antiviral medicines. It is also not clear whether administration of the peptides in particles, which is a key component of the disclosed development (whether the particles are formed before administration or endogenously), would result in effective utilisation of any antiviral action of either component of the particle.
- An amphipathic helical peptide derived from apoA (described by Ananatharamiah in Meth. Enz., 128: 627-647 (1986)) has been shown to prevent fusion of viral membranes with cell membranes, and furthermore prevent the fusion of membranes of infected cells (Srinivas et al. J. Cellular Biochem., 45: 224-237 (1991)). The peptide was also effective at preventing fusion for both HSV1 and HIV (Owens et al., J. Clin. Invest., 86: 1142-1150 (1990)). However, the peptide had no effect at all on attachment of HSV1 at least to cells (Srinivas et al. supra).
- Azuma et al. have reported that peptide derivatives of apoE have a strong antibacterial action, comparable with that of gentamicin (Peptides, 21: 327-330 (2000)). ApoE 133-162 was the most effective, with apoE 134-155 having little effect.
- In the light of the research described above, the inventor conducted experiments to evaluate whether or not peptides derived from ApoE (which are capable of forming helices) have antiviral activity. He found that a tandem repeat of a peptide fragment of ApoE, apoE141-149 (i.e. 2x LRKLRKRLL—SEQ ID No.1), did indeed have an antiviral action. While the inventor does not wish to bound by any hypothesis, he believes that this fragment prevents the attachment of virus particles to cells, resulting in a decrease in the infectivity of the virus as measured by a plaque reduction assay technique. Example 1 illustrates how the peptide is effective against viruses such as HSV1, HSV2 and HIV. Accordingly, this peptide may be effective when applied to virus directly, or when applied to virus in the presence of cells, and therefore the peptide can be used to inactivate free virus particles long before they reach their target cells.
- In the light of the data generated for a tandem repeat of apoE141-149 (i.e. 2x LRKLRKRLL—SEQ ID No.1), the inventors decided to investigate other fragments of apolipoproteins for antiviral activity.
- According to a first aspect of the present invention, there is provided a polypeptide, derivative or analogue thereof comprising a tandem repeat of apoE141-149 of
SEQ ID No 2 or a truncation thereof, characterised in that at least one Leucine (L) residue of SEQ ID No. 2 is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one nitrogen atom. - By “a tandem repeat of apoE141-149 of SEQ ID No. 2” we mean the peptide with the amino acid sequence: LRKLRKRLLLRKLRKRLL. The tandem repeat is referred to herein as apoE141-149dp or apoE141-149r. This peptide is also assigned the
code GIN 1 or GIN1p (wherein p signifies N terminal protection (e.g. by an acetyl group), and C terminal protection (e.g. by an amide group)). - By “a truncation thereof” we mean that the 18mer of SEQ ID No. 2 is reduced in size by removal of amino acids. The reduction of amino acids may be by removal of residues from the C or N terminal of the peptide or may be by deletion of one or more amino acids from within the core of the peptide (i.e. amino acids 2-17 of SEQ ID No. 2).
- By “derivative or analogue thereof” we mean that the amino acids residues are replaced by residues (whether natural amino acids, non-natural amino acids or amino acid mimics) with similar side chains or peptide backbone properties. Additionally the terminals of such peptides may be protected by N and C-terminal protecting groups with similar properties to acetyl or amide groups.
- The inventor conducted exhaustive experiments to assess the antiviral activity of peptides from apolipoproteins and derivatives thereof. Peptides and derivatives from ApoE were a particular focus. To the inventors surprise they found that most of the peptides tested had little or no antiviral effect. The surprising exceptions were peptides according to the first aspect of the invention. Examples 2-7 illustrate the efficacy of the peptides according to the invention compared to a tandem repeat of apoE141-149 and other peptides derived from apolipoproteins.
- The inventor has identified that Tryptophan (W), Arginine (R) or Lysine (K) may be substituted for Leucine in apoE141-149 tandem repeats and that such peptides have surprising antiviral activity. The inventor appreciated that these amino acids had side chains comprising at least 4 carbons and also containing a nitrogen atom. Accordingly it is preferred that the amino acid used to replace the leucine is Tryptophan (W), Arginine (R) or Lysine (K) or derivatives thereof in the peptide according to the first aspect of the invention.
- The inventor has found that peptides in which at least one L has been substituted with a W have particular antiviral activity. It is therefore most preferred that peptides according to the first aspect of the invention comprise a polypeptide, derivative or analogue thereof comprising a tandem repeat of apoE141-149 of
SEQ ID No 2 or a truncation thereof, characterised in that at least one Leucine (L) residue of SEQ ID No. 2 is replaced by a Tryptophan (W). - During development work the inventor noted that W substitutions may be expected to increase the likelihood of the peptide forming an alpha helix and wondered if this may explain the antiviral efficacy of compounds according to the first aspect of the invention. However, he does not believe this explains the surprising efficacy of peptides according to the invention. This is because a number of alternative substitutions would be expected to increase alpha helix formation (e.g see Table 1 for calculation of likelihood of various L substituted peptides forming an alpha helix). However the likelihood of forming a helix (table 1) does not correlate with the antiviral activity of peptides according to the present invention (see Example 5).
-
TABLE 1 Predicted proportion of molecules of various peptides forming alpha-helix in aqueous 0.15M NaCl buffer at 37° C. (%) (using AGADIR secondary structure prediction software available from http://www.embl-heidelberg.de/Services/ serrano/agadir/agadir-start.html) % Amino Acid Substitution Sequence of peptide helix E, Glu ERKERKREEERKERKREE 6.24 A, Ala ARKARKRAAARKARKRAA 1.85 D, Asp DRKDRKRDDDRKDRKRDD 1.59 W, Trp WRKWRKRWWWRKWRKRWW 1.47 M, Met MRKMRKRMMMRKMRKRMM 1.01 Y, Tyr YRKYRKRYYYRKYRKRYY 0.8 F, Phe FRKFRKRFFFRKFRKRFF 0.79 I, Ile IRKIRKRIIIRKIRKRII 0.6 Q, Gln QRKQRKRQQQRKQRKRQQ 0.55 No swap 0.51
The inventors have also noted: -
- 1. The increase from the W substitution is very small (0.51% of
GIN 1p molecules will form a helix, which increases marginally to 1.47% of the W substituted peptide); and - 2. A number of other substitutions would be predicted to increase the proportion of molecules forming an alpha helix at any one time. For instance, substituting L for E or A increases the likelihood of forming an alpha-helix beyond that of a W substitution (to 6.24% and 1.87% respectively). However, both of these substitutions in fact abolished antiviral activity (e.g. see peptide GIN39 in Example 3 or Example 5).
- 1. The increase from the W substitution is very small (0.51% of
- Therefore there is no correlation between likelihood of forming an alpha helix, and the strength of antiviral activity for ‘L-substituted’ peptides according to the invention.
- The efficacy of peptides according to the invention is all the more surprising because substitution of L (Leucine) with amino acids according to the first aspect of the invention will make the peptide less amphipathic. (Table 2 illustrates the accepted order of hydrophobicity of amino acids). A skilled person may actually suspect that making a peptide more amphipathic would confer antiviral character. Therefore, unexpectedly, substitutions according to the invention of SEQ ID No. 2 result in a significant increase in their antiviral activity.
-
TABLE 2 Hydrophobicity of Amino Acids Phe > Leu = Ile > Tyr = Trp > Val > Met > Pro > Cys > Ala > Gly > Thr > Ser > Lys > Gln > Asn > His > Glu > Asp > Arg - As discussed in more detail below,
SEQ ID No 2 may be manipulated according to the first aspect of the invention with a number of different substitutions and deletions to make peptides with antiviral activity. However, it is preferred that the polypeptide according to the first aspect of the invention has at least two W, R or K substitutions, and more preferably three or more W, R or K substitutions. - In addition to one or more L substitutions with W, R or K, it is preferred that at least one further amino acid (preferably at least one further leucine residue) is replaced with Asparagine (N), Tyrosine (Y), Cysteine (C), Methionine (M), Phenylalanine (F), Isoleucine (I), Glutamine (Q) or Histidine (H). It is particularly preferred that such a further substitution is Y or C.
- The substituted polypeptide may comprise 18 amino acids (or derivatives thereof) and thereby correspond to the full length of SEQ ID No. 2. However the inventors have surprisingly found that truncated peptides based on SEQ ID No.2 also have efficacy as antiviral agents. Accordingly preferred peptides or derivatives thereof may have less than 18 amino acids. For instance some peptides according to the first aspect of the invention may be 17, 16, 15, 14, 13, 12, 11, 10 or less amino acids in length.
- Peptides, and derivatives thereof, according to the present invention preferably have an efficacy for inhibiting viral growth such that their IC50 value is 30 μM or less. It is preferred that the IC50 value is 20 μM or less and more preferred that the IC50 value is 10 μM or less.
- Preferred peptides have similar IC50 values between viral species. For instance preferred peptides have similar IC50 values for inhibiting HSV1, HSV2 and HIV growth.
- It will be appreciated that modified amino acids may be substituted into the tandem repeat of apoE141-149 with a number of amino acid variants that may be known to those skilled in the art Such peptides will still have antiviral activity provided that the modification does no significantly alter its chemical characteristics. For instance, hydrogens on the side chain amines of R or K may be replaced with methylene groups (—NH2→—NH(Me) or —N(Me)2).
- Preferred peptides according to the first aspect of the invention have the amino acids sequence:
- (a) WRKWRKRWWWRKWRKRWW (SEQ ID No. 3). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Tryptophan residues. This peptide is designated
GIN 7 when referred to herein.
(b) WRKWRKRWRKWRKR (SEQ ID No. 4). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Tryptophan residues and truncated by the excision ofamino acids GIN 32 when referred to herein.
(c) WRKWRKRWWLRKLRKRLL (SEQ ID No. 5). This peptide corresponds to the full length tandem repeat with a subset of Leucines substituted for tryptophan residues. This peptide is designatedGIN 34 when referred to herein.
(d) WRKWRKRWWRKWRKRWW (SEQ ID No. 52). This peptide corresponds to SEQ ID No. 3 with the W residue atposition 9 deleted. This peptide is designated MU 58 when referred to herein.
(e) WRKWRKRWRKWRKRW (SEQ ID No. 53). This peptide corresponds to SEQ ID No. 3 with the W residues atposition
(f) WRKWRKRWWFRKWRKRWW (SEQ ID No. 54). This peptide corresponds to SEQ ID No. 3 with the W residue atposition 10 substituted with an F. This peptide is designated MU 60 when referred to herein.
(g) WRKWRKRWFFRKWRKRFF (SEQ ID No. 55). This peptide corresponds to SEQ ID No. 3 with the W residues atpositions
(h) WRKCRKRCWWRKCRKRCW (SEQ ID No. 56). This peptide corresponds to SEQ ID No. 3 with the W residues atpositions
(i) LRKLRKRLLWRKWRKRWW (SEQ ID No. 57). This peptide corresponds to SEQ ID No. 2 with the L residues atpositions 10, 13, 17 and 18 substituted with W residues. This peptide is designated MU 111 when referred to herein.
(j) LRKLRKRLLLRKLRKRWW (SEQ ID No. 58). This peptide corresponds to SEQ ID No. 2 with the L residues at positions 17 and 18 substituted with W residues. This peptide is designated MU 112 when referred to herein.
(k) LRKLRKRLLWRKWRKRLL (SEQ ID No. 59). This peptide corresponds to SEQ ID No. 2 with the L residues atpositions 10 and 13 substituted with W residues. This peptide is designated MU 113 when referred to herein.
(l) WRKWRKRLLLRKLRKRLL (SEQ ID No. 60). This peptide corresponds to SEQ ID No. 2 with the L residues atpositions
(m) WRKLRKRLLLRKLRKRLL (SEQ ID No. 61). This peptide corresponds to SEQ ID No. 2 with the L residue atposition 1 substituted with W residues. This peptide is designated MU 115 when referred to herein.
(n) WRKWRKFFFRKWRKRWW (SEQ ID No. 62). This peptide corresponds to SEQ ID No. 3 with the W residues atpositions position 7 deleted. This peptide is designated MU 116 when referred to herein.
(0) WRKWRKRWWFRKFRKRFF (SEQ ID No. 63). This peptide corresponds to SEQ ID No. 3 with the W residues atpositions 10, 13, 17 and 18 substituted with F residues. This peptide is designated MU 117 when referred to herein.
(p) RRKRRKRRRRRKRRKRRR (SEQ ID No. 64). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Arginine (R) residues. This peptide is designated MU 16 when referred to herein.
(q) KRKKRKRKKKRKKRKRKK (SEQ ID No. 65). This peptide corresponds to the full length tandem repeat with all Leucines substituted for Lysine (K) residues. This peptide is designated MU 18 when referred to herein. - The inventor has also appreciated that peptides may be employed according to the invention that comprise more than just a simple dimer tandem repeat of ApoE141-149 or a truncation thereof. For instance, peptides comprising a trimer or greater number of repeats may be employed as antiviral agents.
- In a further embodiment of the invention, antiviral peptides may be synthesised that comprise a peptide as defined above to which further amino acids have been added. For instance, one, two, three or more amino acids may be added to the C or N terminals of a peptide derived from SEQ ID No. 2. Alternatively the peptide may comprise a tandem repeat of a peptide that is larger than the nine amino acids of SEQ ID No. 1. Such peptides may have amino acids added to the N terminal, C terminal and/or between the 9th and 10th amino acids of SEQ ID No. 2. It is most preferred that the amino acid is added to C terminal and also between the 9th and 10th amino acids of SEQ ID No. 2. It will be appreciated that such peptides may then be modified as described above for peptides derived from SEQ ID No. 2. By way of example WRKWRKRWWRWRKWRKRWWR (SEQ ID No. 66) represents another preferred peptide according to the present invention. This peptide corresponds to the full length tandem repeat of ApoE141-150 (i.e. a tandem repeat of LRKLRKRLLR—SEQ ID No. 67) with all Leucines substituted for Tryptophan residues. This peptide is designated MU 83 when referred to herein.
- During the development of derivatives of tandem repeats of apoE141-149 according to the first aspect of the invention, it was appreciated that truncations of SEQ ID No.2, and variants thereof, also had surprising antiviral activity. These include:
- LRKLRKRLLLRKLRK (SEQ ID No. 7). This peptide corresponds to a truncated form of the full length tandem repeat with residues 16, 17 and 18 deleted. This peptide has the advantage that the peptide is shorter than
GIN 1 and is therefore cheaper to manufacture. This peptide is designatedGIN 4 when referred to herein.
LRKLRKRLRKLRKR (SEQ ID No. 8). This peptide corresponds to the full length tandem repeat truncated by the excision ofamino acids GIN 8 when referred to herein.
LRKLRKLRKLRKLRKLRK (SEQ ID No. 9). This peptide corresponds to a variation of the full length tandem repeat comprising a repeat of the LRK motif. This peptide is designatedGIN 9 when referred to herein.
Furthermore YRKYRKRYYYRKYRKRYY (SEQ ID No. 6) was found to be effect as an antiviral agent. This peptide corresponds to the full length tandem repeat of apoE141-149 with all Leucines substituted for Tyrosine residues. This peptide is designated GIN 41 when referred to herein. - According to a second aspect of the invention there is provided a polypeptide, derivative or analogue thereof according to the first aspect of the invention or a peptide of SEQ ID No. 6, 7, 8 or 9 for use as a medicament.
- According to a third aspect of the invention there is provided the use of a polypeptide, derivative or analogue thereof according to the first aspect of the invention or a peptide of SEQ ID No. 6, 7, 8 or 9 for the manufacture of a medicament for treating viral infections.
- It will be appreciated that the therapeutic effects of polypeptides, derivatives or analogues according to the first aspect of the invention may also be mediated “indirectly” by agents that increase the activity of such polypeptides, derivatives or analogues. The present invention provides the first medical use of such agents.
- Thus, according to a fourth aspect of the invention, there is provided an agent capable of increasing the biological activity of a polypeptide, derivative or analogue according to the first aspect of the invention for use as a medicament.
- Agents capable of increasing the biological activity of polypeptides, derivatives or analogues according to the invention may achieve their effect by a number of means. For instance, such agents may increase the expression of such polypeptides, derivatives or analogues. Alternatively (or in addition) such agents may increase the half-life of polypeptides, derivatives or analogues according to the invention in a biological system, for example by decreasing turnover of the polypeptides, derivatives or analogues.
- Due to their increased biological activity polypeptides, derivatives or analogues according to the first three aspects of the invention are of utility as antiviral agents.
- Polypeptides, derivatives or analogues according to the first, second and third aspects of the invention may be used in the treatment of a number of viral infections. The virus may be any virus, and particularly an enveloped virus. Preferred viruses are poxviruses, iridoviruses, togaviruses, or toroviruses. A more preferred virus is a filovirus, arenavirus, bunyavirus, or a rhabdovirus. An even more preferred virus is a paramyxovirus or an orthomyxovirus. It is envisaged that virus may preferably include a hepadnavirus, coronavirus, flavivirus, or a retrovirus. Preferably, the virus includes a herpesvirus or a lentivirus. In preferred embodiments, the virus may be Human Immunodeficiency Virus (HIV), Human herpes simplex virus type 2 (HSV2), or Human herpes simplex virus type 1 (HSV1).
- Polypeptides, derivatives or analogues according to the first, second and third aspects of the invention may be used to treat viral infections as a monotherapy (i.e. use of the compound alone) or in combination with other compounds or treatments used in antiviral therapy (e.g. acyclovir, gangcylovir, ribavirin, interferon, anti-HIV medicaments including nucleoside, nucleotide or non-nucleoside inhibitors of reverse transcriptase, protease inhibitors and fusion inhibitors.)
- The polypeptides, derivatives or analogues may be used as a prophylactic (to prevent the development of a viral infection) or may be used to treat existing infections.
- Derivatives of polypeptides according to the invention may include derivatives that increase or decrease the polypeptide's half-life in vivo. Examples of derivatives capable of increasing the half-life of polypeptides according to the invention include peptoid derivatives of the polypeptides, D-amino acid derivatives of the polypeptides, and peptide-peptoid hybrids.
- Polypeptides according to the invention may be subject to degradation by a number of means (such as protease activity in biological systems). Such degradation may limit the bioavailability of the polypeptides and hence the ability of the polypeptides to achieve their biological function. There are wide ranges of well-established techniques by which peptide derivatives that have enhanced stability in biological contexts can be designed and produced. Such peptide derivatives may have improved bioavailability as a result of increased resistance to protease-mediated degradation. Preferably a peptide derivative or analogue suitable for use according to the invention is more protease-resistant than the peptide from which it is derived. Protease-resistance of a peptide derivative and the peptide from which it is derived may be evaluated by means of well-known protein degradation assays. The relative values of protease resistance for the peptide derivative and peptide may then be compared.
- Peptoid derivatives of the peptides of the invention may be readily designed from knowledge of the structure of the peptide according to the first aspect of the invention. Commercially available software may be used to develop peptoid derivatives according to well-established protocols.
- Retropeptoids, (in which all amino acids are replaced by peptoid residues in reversed order) are also able to mimic antiviral peptides derived from apolipoproteins. A retropeptoid is expected to bind in the opposite direction in the ligand-binding groove, as compared to a peptide or peptoid-peptide hybrid containing one peptoid residue. As a result, the side chains of the peptoid residues are able point in the same direction as the side chains in the original peptide.
- A further embodiment of a modified form of polypeptides according to the invention comprises D-amino acid forms of the polypeptides. The preparation of peptides using D-amino acids rather than L-amino acids greatly decreases any unwanted breakdown of such an agent by normal metabolic processes, decreasing the amounts of agent which need to be administered, along with the frequency of its administration.
- The polypeptides, analogues, or derivatives of the invention represent products that may advantageously be expressed by biological cells.
- Thus, the present invention also provides, in a fifth aspect, a nucleic acid sequence encoding a polypeptide, derivative or analogue according to the first aspect of the invention.
- The nucleic acids encoding apoE141-149 has the DNA sequence cttcgtaaacttcgtaaacgtcttctt (SEQ ID. No. 10) whereas
GIN 1 has the sequence cttcgtaaacttcgtaaacgtcttcttcttcgtaaacttcgtaaacgtcttctt (SEQ ID. No. 11). - Preferred nucleic acids according to the fifth aspect of the invention encode the peptides identified herein as
GIN -
(SEQ ID No. 16) cttcgtaaac ttcgtaaact tcgtaaactt cgtaaacttc gtaaacttcg taaa; (SEQ ID No. 12) tggcgtaaat ggcgtaaacg ttggtggtgg cgtaaatggc gtaaacgttg gtgg; (SEQ ID No. 17) cttcgtaaac ttcgtaaacg tcttcgtaaa cttcgtaaac gt; (SEQ ID No. 18) cttcgtaaac ttcgtaaact tcgtaaactt cgtaaacttc gtaaacttcg taaa; (SEQ ID No. 13) tggcgtaaat ggcgtaaacg ttggcgtaaa tggcgtaaac gt; (SEQ ID No. 14) tggcgtaaat ggcgtaaacg ttggtggctt cgtaaacttc gtaaacgtct tctt,; and (SEQ ID No. 15) tatcgtaaat atcgtaaacg ttattattat cgtaaatatc gtaaacgtta ttat. - A skilled person will appreciate that the nucleic acid sequence of other preferred peptides according to the present invention may be readily generated.
- It will be appreciated that, due to redundancy in the genetic code, a nucleic acid sequence in accordance with the fifth aspect of the invention may vary from the naturally occurring ApoE gene providing a codon encodes a polypeptide, derivative or analogue thereof in accordance with the first aspect of the invention.
- It will be appreciated that polypeptides, derivatives and analogues according to the invention represent favourable agents to be administered by techniques involving cellular expression of nucleic acid sequences encoding such molecules. Such methods of cellular expression are particularly suitable for medical use in which the therapeutic effects of the polypeptides, derivatives and analogues are required over a prolonged period.
- Thus according to a sixth aspect of the present invention there is provided a nucleic acid sequence according to the fifth aspect of the invention for use as a medicament.
- The nucleic acid may preferably be an isolated or purified nucleic acid sequence. The nucleic acid sequence may preferably be a DNA sequence.
- The nucleic acid sequence may further comprise elements capable of controlling and/or enhancing its expression. The nucleic acid molecule may be contained within a suitable vector to form a recombinant vector. The vector may for example be a plasmid, cosmid or phage. Such recombinant vectors are highly useful in the delivery systems of the invention for transforming cells with the nucleic acid molecule.
- Recombinant vectors may also include other functional elements. For instance, recombinant vectors can be designed such that the vector will autonomously replicate in the cell. In this case elements that induce nucleic acid replication may be required in the recombinant vector. Alternatively, the recombinant vector may be designed such that the vector and recombinant nucleic acid molecule integrates into the genome of a cell. In this case nucleic acid sequences, which favour targeted integration (e.g. by homologous recombination) are desirable. Recombinant vectors may also have DNA coding for genes that may be used as selectable markers in the cloning process.
- The recombinant vector may also further comprise a promoter or regulator to control expression of the gene as required.
- The nucleic acid molecule may (but not necessarily) be one, which becomes incorporated in the DNA of cells of the subject being treated. Undifferentiated cells may be stably transformed leading to the production of genetically modified daughter cells (in which case regulation of expression in the subject may be required e.g. with specific transcription factors or gene activators). Alternatively, the delivery system may be designed to favour unstable or transient transformation of differentiated cells in the subject being treated. When this is the case, regulation of expression may be less important because expression of the DNA molecule will stop when the transformed cells die or stop expressing the protein (ideally when the required therapeutic effect has been achieved).
- The delivery system may provide the nucleic acid molecule to the subject without it being incorporated in a vector. For instance, the nucleic acid molecule may be incorporated within a liposome or virus particle. Alternatively a “naked” nucleic acid molecule may be inserted into a subject's cells by a suitable means e.g. direct endocytotic uptake.
- The nucleic acid molecule may be transferred to the cells of a subject to be treated by transfection, infection, microinjection, cell fusion, protoplast fusion or ballistic bombardment. For example, transfer may be by ballistic transfection with coated gold particles, liposomes containing the nucleic acid molecule, viral vectors (e.g. adenovirus) and means of providing direct nucleic acid uptake (e.g. endocytosis) by application of the nucleic acid molecule directly.
- It will be appreciated that the polypeptides, agents, nucleic acids or derivatives according to the present invention may be used in a monotherapy (i.e. use of polypeptides, agents, nucleic acids or derivatives according to the invention alone to prevent and/or treat a viral infection). Alternatively, polypeptides, agents, nucleic acids or derivatives according to the invention may be used as an adjunct, or in combination with, known therapies.
- Polypeptides, agents, nucleic acids or derivatives according to the invention may be combined in compositions having a number of different forms depending, in particular on the manner in which the composition is to be used. Thus, for example, the composition may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle, transdermal patch, liposome or any other suitable form that may be administered to a person or animal. It will be appreciated that the vehicle of the composition of the invention should be one which is well tolerated by the subject to whom it is given, and is preferably adapted to enable delivery of the polypeptides, agents, nucleic acids or derivatives to the target tissue.
- Compositions comprising polypeptides, agents, nucleic acids or derivatives according to the invention may be used in a number of ways. For instance, oral administration may be required in which case the compound may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid. Alternatively the composition may be administered by injection into the blood stream. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion). The compounds may be administered by inhalation (e.g. intranasally).
- Compositions may be formulated for topical use. For instance, ointments may be applied to the skin, areas in and around the mouth or genitals to treat specific viral infections. Topical application to the skin is particularly useful for treating viral infections of the skin or as a means of transdermal delivery to other tissues. Intravaginal administration is effective for treating sexually transmitted diseases (including AIDS).
- Polypeptides, agents, nucleic acids or derivatives may also be incorporated within a slow or delayed release device. Such devices may, for example, be inserted on or under the skin, and the compound may be released over weeks or even months. Such devices may be particularly advantageous when long term treatment with a polypeptide, agent, nucleic acid or derivative according to the invention is required and which would normally require frequent administration (e.g. at least daily injection).
- It will be appreciated that the amount of a polypeptide, agent, nucleic acid or derivative that is required is determined by its biological activity and bioavailability which in turn depends on the mode of administration, the physicochemical properties of the polypeptide, agent, nucleic acid or derivative employed and whether the polypeptide, agent, nucleic acid or derivative is being used as a monotherapy or in a combined therapy. The frequency of administration will also be influenced by the above-mentioned factors and particularly the half-life of the polypeptide, agent, nucleic acid or derivative within the subject being treated.
- Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular polypeptide, agent, nucleic acid or derivative in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
- It will be appreciated that a skilled person will be able to calculate required doses, and optimal concentrations of the peptides at a target tissue, based upon the pharmacokinetics of the peptides and in particular the IC50 values given in the Examples.
- Generally, a daily dose of between 0.01 μg/kg of body weight and 0.5 g/kg of body weight of polypeptides, agents, nucleic acids or derivatives according to the invention may be used for the prevention and/or treatment of a viral infection, depending upon which specific polypeptide, agent, nucleic acid or derivative is used. More preferably, the daily dose is between 0.01 mg/kg of body weight and 200 mg/kg of body weight, and most preferably, between approximately 1 mg/kg and 100 mg/kg.
- Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. in vivo experimentation, clinical trials, etc.), may be used to establish specific formulations of polypeptides, agents, nucleic acids or derivatives according to the invention and precise therapeutic regimes (such as daily doses of the polypeptides, agents, nucleic acids or derivatives and the frequency of administration).
- Daily doses may be given as a single administration (e.g. a single daily injection). Alternatively, the polypeptide, agent, nucleic acid or derivative used may require administration twice or more times during a day. As an example, polypeptides, agents, nucleic acids or derivatives according to the invention may be administered as two (or more depending upon the severity of the condition) daily doses of between 25 mg and 7000 mg (i.e. assuming a body weight of 70 kg). A patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3 or 4 hourly intervals thereafter. Alternatively, a slow release device may be used to provide optimal doses to a patient without the need to administer repeated doses.
- This invention provides a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide, agent, nucleic acid or derivative according to the invention and optionally a pharmaceutically acceptable vehicle. In one embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 800 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 500 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.01 mg to about 250 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.1 mg to about 60 mg. In another embodiment, the amount of the polypeptide, agent, nucleic acid or derivative is an amount from about 0.1 mg to about 20 mg.
- This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a polypeptide, agent, nucleic acid or derivative according to the invention and a pharmaceutically acceptable vehicle. A “therapeutically effective amount” is any amount of a polypeptide, agent, nucleic acid or derivative according to the first aspect of the invention which, when administered to a subject provides prevention and/or treatment of a viral infection. A “subject” is a vertebrate, mammal, domestic animal or human being.
- A “pharmaceutically acceptable vehicle” as referred to herein is any physiological vehicle known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.
- In a preferred embodiment, the pharmaceutical vehicle is a liquid and the pharmaceutical composition is in the form of a solution. In another embodiment, the pharmaceutically acceptable vehicle is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical vehicle is a gel and the composition is in the form of a cream or the like.
- A solid vehicle can include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the vehicle is a finely divided solid that is in admixture with the finely divided active polypeptide, agent, nucleic acid or derivative. In tablets, the active polypeptide, agent, nucleic acid or derivative is mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active polypeptide, agent, nucleic acid or derivative. Suitable solid vehicles include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active polypeptide, agent, nucleic acid or derivative can be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration. The liquid vehicle for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and particularly subcutaneous, intracerebral or intracerebroventricular injection. The polypeptide, agent, nucleic acid or derivative may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. Vehicles are intended to include necessary and inert binders, suspending agents, lubricants, flavourants, sweeteners, preservatives, dyes, and coatings.
- Polypeptides, agents, nucleic acids or derivatives according to the invention can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- Polypeptides, agents, nucleic acids or derivatives according to the invention can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- The invention will be further described, by way of example only, with reference to the following Examples and figures in which:—
-
FIG. 1 shows the effect of apoE141-149dp and apoE263-286 on HSV1 infectivity. (points are derived from the average of up to four values) as described in Example 1; -
FIG. 2 shows the effect of apoE141-149dp or apoE263-286 on HSV2 infectivity (points are derived from the average of up to four values) as described in Example 1; -
FIG. 3 illustrates inhibition of HIV-1 p24 production, as measured by ELISA, by apoE141-149r, and apoE263-286 in acutely infected U937 cells (values are the average of three experiments) as described in Example 1 (ApoE141-149dp was significantly active against HIV (ANOVA, p<0.001), whereas the activity of apoE263-286 against HIV did not reach significance (ANOVA; 0.06<p<0.62)); -
FIG. 4 illustrates the effect of 4 peptides (GIN1, 1p, 2 and 3) on HSV1 infectivity as described in Example 2; -
FIG. 5 illustrates the effect of 4 peptides (GIN 4-7) on HSV1 infectivity as described in Example 2; -
FIG. 6 illustrates the effect of 4 peptides (GIN 8-11) on HSV1 infectivity as described in Example 2; -
FIG. 7 compares and illustrates the effect ofpeptides GIN 7,GIN 32,GIN 34, andGIN 1p on HSV1 infectivity as described in Example 2; -
FIG. 8 illustrates the anti-HIV action of peptide GIN7 against HIV isolate SF162, grown in NP-2 glioma cells overexpressing CCR5 co-receptors as described in Example 4; -
FIG. 9 shows typical mass spectrometry data for GIN7 and illustrates that the peptide was >95% purity; -
FIG. 10 shows typical HPLC data for GIN7 and illustrates that the peptide was >95% purity. - Experiments were conducted with ApoE141-149 to establish whether or not the peptide had any efficacy as an antiviral agent.
-
FIG. 1 and table 1 show typical results for the test for anti-HSV1 activity. The assay involved treating confluent Vero cells in 24-well plates with medium containing virus and varying amounts of peptide for one hour, followed by removal of this inoculum, and addition of viscous ‘overlay’ medium, containing 0.2% high viscosity carboxymethylcellulose. The overlay medium only allows infection of those cells immediately adjacent to an infected cell. After 2 days incubation and then fixation and staining, small patches of infected cells (or ‘plaques’) are visible, which are counted. Each of these corresponds to the infection of a single cell during the one hour inoculation. ApoE141-149dp produced a 40% reduction in plaque number at a concentration of around 20 μM. Note the peptide was only present in the experimental system for 1 hour. -
TABLE 1 HSV1 plaque formation in Vero cells after inoculation with virus containing either apoE141-149dp or apoE263-286. ApoE141-149dp ApoE263-286 [μM] 1 2 3 4 Mean ± sd 1 2 3 4 Mean ± sd 0 96 102 123 107 ± 14.2 5 129 106 103 100 110 ± 13.2 113 119 122 126 120 ± 5.5 10 73 87 76 89 81 ± 7.9 116 124 102 114 ± 11.1 20 68 67 63 63 65 ± 2.6 148 112 133 114 127 ± 17.0 30 72 71 56 66 ± 9.0 134 109 114 125 121 ± 11.2 40 64 65 53 68 63 ± 6.6 120 113 125 144 126 ± 11.2 Values for untreated wells are underlined. -
FIG. 2 and table 2 show typical results for the test for anti-HSV2 activity. The assay was carried out as for the anti-HSV1 assay, except Hep-2 cells were used rather than Vero cells. ApoE141-149dp produced a 50% reduction in plaque number at a concentration of around 20 μM. Again note that the peptide was only present in the experimental system for 1 hour. -
TABLE 2 HSV2 plaque formation in HEp-2 cells after inoculation with virus containing either apoE141-149dp or apoE263-286. ApoE141-149dp ApoE263-286 [μM] 1 2 3 4 Mean ± sd 1 2 3 4 Mean ± sd 0 156 137 162 152 152 ± 10.7 5 160 134 140 130 141 ± 13.3 135 160 161 152 152 ± 12.0 10 125 113 131 132 125 ± 8.7 157 121 151 134 141 ± 16.1 20 82 72 73 81 77 ± 5.2 118 150 182 134 146 ± 27.3 30 76 77 71 72 74 ± 2.9 118 117 103 159 124 ± 24.2 40 51 59 69 49 57 ± 9.1 132 144 125 124 131 ± 24.2 Values for untreated wells are underlined. -
FIG. 3 and table 3 show typical results for the test for anti-HIV activity. The assay was carried out by incubating HIV infected U937 cells in the presence of various levels of peptide for 7 days, followed by assay for levels of the HIV protein p24 in the cells using an Enzyme Linked Immunoabsorbant Assay (ELISA) technique. ApoE141-149dp produced a 95% reduction in infectivity at 20 μM. ApoE263-286 produced a 20% reduction in infectivity at 20 μM, which did not reach statistical significance. - The effect on HIV appears at lower peptide concentrations, though this may be due to peptide being in contact with cells for 7 days, as opposed to just 1 hour in plaque reduction assays with herpes viruses.
-
TABLE 3 Inhibition of HIV-1 p24 production, as measured by ELISA, by apoE141-149dp, and apoE263-286 in acutely infected U937 cells. % Decrease in HIV p24 Production ApoE141-149dp ApoE263-286 [μM] Exp. 1 Exp. 2 Exp. 3 Mean ± sd Exp. 1 Exp. 2 Exp. 3 Mean ± sd 0 0 0 0 0 0 0 0 0 10 91.66 70.31 89.85 83.94 ± 11.84 31.75 8.50 29.38 23.21 ± 12.79 20 96.87 95.08 93.10 95.02 ± 1.89 7.69 29.71 30.91 22.77 ± 13.07 30 95.94 88.63 87.77 90.78 ± 4.49 37.94 27.83 41.78 35.85 ± 7.21 40 96.80 95.47 95.33 95.87 ± 0.81 23.50 30.08 48.04 38.87 ± 12.70 50 95.73 93.25 95.38 94.79 ± 1.34 33.36 41.45 45.66 40.16 ± 6.25 - The results presented in 1.1-1.3 illustrate that ApoE141-149dp was more efficacious than ApoE263-286.
- In the light of these results, the inventors proceeded to test other peptides generated from apolipoproteins to investigate whether or not such peptides had antiviral activity (see Example 2).
- Given the knowledge gained by the inventors following the work reported in Example 1, experiments were conducted to evaluate the antiviral effects of a large number of peptides derived from apolipoproteins. Surprisingly, the inventors found that only a minority of the peptides tested had antiviral effects (see 2.2). Such peptides represent peptides according to the invention.
- African Green Monkey Kidney (Vero) cells were maintained in Eagle's minimum essential medium with Earle's salt (EMEM) and supplemented with 10% foetal calf serum (heat-inactivated), 4 mM L-glutamine, and 1% (v/v) nonessential amino acids, plus penicillin and streptomycin (100 IU/mg and 100 mg/ml, respectively) (maintenance medium referred to as 10% EMEM). The cells were incubated at 37° C. in a humidified atmosphere of air with 5% CO2.
- On harvesting, monolayers were washed in phosphate-buffered saline (PBS), and dislodged by incubating with trypsin in PBS for 30 min, before inactivating trypsin by addition of an equal volume of 10% EMEM and centrifuging at 500 g (5 min, 4° C.). Cell pellets were resuspended in 10% EMEM, prior to cell counting and seeding of 24-well plates. For antiviral assays, medium containing only 0.5% FCS was used (referred to as 0.5% EMEM).
- Three separate passages of HSV1 virus were prepared by infecting Vero cells, and preparing semi-pure suspensions of virus from tissue culture supernatant and cell lysates, before freezing aliquots of virus at −85° C. Viral infectivity was assessed by carrying out plaque assays on serial dilutions of thawed aliquots (expressed in pfu/ml).
- Peptides were obtained in lyophilised form from a commercial supplier (AltaBioscience, University of Birmingham or Advanced Biomedical), and were produced at 5 micromole scale. N-terminals were protected by addition of an acetyl group, and the C-terminals were protected by addition of an amide group.
- Molecular weight of peptides was confirmed by laser desorption mass spectrometry using a
Finnigan LASERMAT 2000 MALDI-time of flight mass analyzer or a Scientific Analysis Group MALDI-TOF mass spectrometer. HPLC purification of peptides was performed using a Vydac analytical C-4 reverse phase column, using 0.1% TFA and 0.1% TFA/80% acetonitrile as solvents, or for some peptides an ACE C18 Reverse Phase column, using 0.05% TFA and 60% acetonitrile as solvents. Typical mass spectrometry data and high performance liquid chromatography (HPLC) traces (purity >95%) for peptide GIN 7 (SEQ ID No. 3) are shown inFIGS. 9 and 10 . - Small quantities of peptide were weighed in sterile Eppendorf tubes, before addition of sufficient 0.5% EMEM to produce a 1.5 mM stock solution, which was frozen at −20° C. in aliquots.
- Vero cells were seeded at 125,000 cells per well in 10% EMEM, and were incubated overnight resulting in confluent monolayers. Peptides were diluted in 0.5% EMEM to give 2× final desired concentration, and 100 μl aliquots were arranged on 96-well plates in arrangement to be used for 24-well plate; control wells containing normal 0.5% EMEM were also prepared. Virus stocks (p3) were thawed, and diluted in 0.5% EMEM such that there were around 100 pfu in 100 μl. Each 24-well plate was inoculated separately. Firstly 100 μl of virus stock was added to the peptide or control medium arranged on a 96-well plate. This was incubated at 37° C. for ten minutes before inoculation. Medium was removed from four wells of a 24-well plate containing confluent Vero, and the 200 μl inoculum added to the appropriate well. Once all wells were treated, the 24-well plate was incubated for a further 60-80 minutes. Finally the peptide-containing inoculum was removed, and 1 ml of 1% EMEM containing 1% carboxymethylcellulose was added to each well. Plates were incubated for a further 22 hours or in some
experiments 40 hours, before removal of overlay, and addition of 10% formaldehyde in PBS. After a further one hour incubation, fixative was removed, monolayers washed several times with tap water, and stained with carbol fuchsin solubilised in water. After 30 minutes stain was removed, and plates washed several times with tap water, before being air dried. Plaques were counted using an Olympus IX70 Inverting Microscope, and antiviral effect expressed as a percentage of the control value for each peptide concentration. The IC50 was calculated from plots of inhibitory effect against peptide concentration. - Vero cells were seeded in 96-well plates at 30,000 cells per well in 10% EMEM, and were incubated overnight resulting in confluent monolayers. GIN peptides were diluted in 0.5% EMEM to give final desired concentration, and 100 μl aliquots were arranged on separate non-cell containing 96-well plates, prior to taking Vero 96-well plates, removing 10% EMEM, and adding 0.5% EMEM containing peptides. After incubating for 48 hours, 25 μl of 1.5 mg/ml MTT solution (in 0.5% EMEM) was added per well, and plates returned to incubator for one hour. Finally, medium was removed from wells, and blue formazan crystals solubilised by addition of 100 μl of dimethylsulphoxide (DMSO). Absorbance of resulting solutions was then measured at 570 nm, and toxic effect expressed as a percentage of the control value for each peptide concentration. Where possible, the EC50 was calculated from plots of toxic effect against peptide concentration. Fortunately, no evidence of toxicity was found for the cell line tested, using peptide at 40 μM exposed to cells for 2 days.
- 2.2 Results Table 4 summarises data obtained for 16 peptides identified as
GIN 1,GIN 1p and GIN 2-15. -
TABLE 4 SEQ ID Apparent Peptide No. IC50 (μM) Sequence Size GIN 1 2 16.5 LRKLRKRLLLRKLRKRLL 18 GIN 1p2 10 LRKLRKRLLLRKLRKRLL 18 GIN 224 >40 LRKRLLLRKLRKRLL 15 GIN 331 No RLLLRKLRKRLL 12 Activity GIN 4 7 29.5 LRKLRKRLLLRKLRK 15 GIN 525 >40 LRKLRKRLLLRK 12 GIN 626 >40 ERKERKREEERKERKREE 18 GIN 73 <5 WRKWRKRWWWRKWRKRWW 18 GIN 88 13 LRKLRKRLRKLRKR 14 GIN 99 15.5 LRKLRKLRKLRKLRKLRK 18 GIN 1022 39 RLLRLLRLLRLLRLLRLL 18 GIN 1120 36.5 QSTEELRVRLASHLRKLRKRLL 22 GIN 12 27 >40 LRKLRKRLLR DADDLQKRLA 20 GIN 13 28 >40 RDADDLQKR RDADDLQKR 20 GIN 14 29 >40 GERLRARMEGERLRARME 18 GIN 15 30 >40 RLRARMEEMRLRARMEEM 18 -
FIG. 4 illustrates that the ApoE141-149dp (labelled as GIN 1) had good efficacy for reducing HSV1 infectivity. Arelated peptide GIN 1p (GIN 1 with N and C terminal protection) had similar efficacy. - As illustrated in Table 4 the inventors tested a number of other related peptides (identified as
GIN 2,GIN 3,GIN 4,GIN 5,GIN 6,GIN 10,GIN 11, GIN 12, GIN 13, GIN 14 and GIN 15) and it was found that they had no, or poor, efficacy for reducing viral infectivity. - In addition, the inventor found to his surprise, that a subset of the tested peptides (which are peptides according to the present invention) were effective as antiviral agents.
FIG. 5 illustrates that the peptide designatedGIN 7 had efficacy for reducing HSV-1 infectivity. -
FIG. 6 illustrates that the peptides designatedGIN 8 andGIN 9 also had efficacy for reducing HSV-1 infectivity. - Table 5 and
FIG. 4 a illustrate that a number of peptides related or similar to the ApoE141-149dp peptide (identified as peptides GIN 17-31 in Table 4a) had no, or poor, efficacy for reducing viral infectivity. The inventors had rationally designed these molecules in the expectation that they may have anti-HSV1 activity and, based on the data presented in Table 4, a skilled person may have expected such peptides to have similar efficacy to those claimed according to the invention. The fact that these peptides had little effect makes the usefulness of the claimed peptides all the more surprising. -
TABLE 5 Apparent SEQ IC50 Peptide ID No. (μM) Sequence Size GIN 17 33 NA RALVDTLKFVTQAEGAK 17 GIN 18 34 NA PYLDDFQKKWQEEMELYRQKVE 22 GIN 19 35 NA PLGEEMRDRARAHVDALRTHLA 22 GIN 2036 NA PYSDELRQRLAARLEALKENGG 22 GIN 21 37 NA ARLAEYHAKATEHLSTLSEKAK 22 GIN 22 19 36 DWLKAFYDKVAEKLKEAF 18 GIN 23 38 NA PVLDEFREKLNEELEALKQKMK 22 GIN 24 39 NA VTDYGKDLMEKVKSPELQ 18 GIN 25 40 NA VTDYGKDLMEKVKEWLNS 18 GIN 26 41 NA NFHAMFQPFLEMIHEAQQ 28 GIN 27 42 NA CKNKEKKCCKNKEKKC 18 GIN 28 43 NA LRKEKKRLLLRKEKKRLL 18 GIN 29 21 38.5 HMLDVMQDHFSRASSIIDEL 20 GIN 3044 NA LQVAERLTRKYNELLKSYQ 19 GIN 3145 NA KFMETVAEKALQEYRK 16 - A further set of experiments was conducted on an expanded number of peptides to further evaluate the effect of peptides according to the invention against HS V-1. Table 6 confirms that the peptides designated
GIN 1p andGIN 7 had anti-HSV-1 properties, whereas the peptides designatedGIN -
FIG. 7 compares and illustrates the effect ofpeptides GIN 7,GIN 32,GIN 34, andGIN 1p on HSV1 infectivity. -
TABLE 6 Peptide Code SEQ ID No. Nucleic acid SEQ ID No. Sequence IC50 (μM) 7 SEQ ID No. 3 SEQ ID No. 12 WRKWRKRWWWRKWRKRWW 3.5 34 SEQ ID No. 5 SEQ ID No. 14 WRKWRKRWWLRKLRKRLL 6 32 SEQ ID No. 4 SEQ ID No. 13 WRKWRKRWRKWRKR 10 41 SEQ ID No. 6 SEQ ID No. 15 YRKYRKRYYYRKYRKRYY 16 1p SEQ ID No. 2 SEQ ID No. 11 LRKLRKRLLLRKLRKRLL 17 activity low: 4 SEQ ID No. 7 SEQ ID No. 16 LRKLRKRLLLRKLRK 29.5 22 SEQ ID No. 19 NA DWLKAFYDKVAEKLKEAF 36 11 SEQ ID No. 20 NA QSTEELRVRLASHLRKLRKRLL 36.5 29 SEQ ID No. 21 NA HMLDVMQDHFSRASSIIDEL 38.5 10 SEQ ID No. 22 NA RLLRLLRLLRLLRLLRLL 39 44 SEQ ID No. 23 NA LRQLRQRLLLRQLRQRLL 40 2 SEQ ID No. 24 NA LRKRLLLRKLRKRLL >40 5 SEQ ID No. 25 NA LRKLRKRLLLRK >40 6 SEQ ID No. 26 NA ERKERKREEERKERKREE >40 12 SEQ ID No. 27 NA LRKLRKRLLR DADDLQKRLA >40 13 SEQ ID No. 28 NA RDADDLQKR RDADDLQKR >40 14 SEQ ID No. 29 NA GERLRARMEGERLRARME >40 15 SEQ ID No. 30 NA RLRARMEEMRLRARMEEM >40 No activity: apoE 141-149 SEQ ID No. 1 SEQ ID No. 10 LRKLRKRLL NA 3 SEQ ID No. 31 NA RLLLRKLRKRLL NA 6 SEQ ID No. 32 NA ERKERKREEERKERKREE NA 17 SEQ ID No. 33 NA RALVDTLKFVTQAEGAK NA 18 SEQ ID No. 34 NA PYLDDFQKKWQEEMELYRQKVE NA 19 SEQ ID No. 35 NA PLGEEMRDRARAHVDALRTHLA NA 20 SEQ ID No. 36 NA PYSDELRQRLAARLEALKENGG NA 21 SEQ ID No. 37 NA ARLAEYHAKATEHLSTLSEKAK NA 23 SEQ ID No. 38 NA PVLDEFREKLNEELEALKQKMK NA 24 SEQ ID No. 39 NA VTDYGKDLMEKVKSPELQ NA 25 SEQ ID No. 40 NA VTDYGKDLMEKVKEWLNS NA 26 SEQ ID No. 41 NA NFHAMFQPFLEMIHEAQQ NA 27 SEQ ID No. 42 NA CKNKEKKCCKNKEKKC NA 28 SEQ ID No. 43 NA LRKEKKRLLLRKEKKRLL NA 30 SEQ ID No. 44 NA LQVAERLTRKYNELLKSYQ NA 31 SEQ ID No. 45 NA KFMETVAEKALQEYRK NA 39 SEQ ID No. 46 NA ARKARKRAAARKARKRAA NA 40 SEQ ID No. 47 NA MRKMRKRMMMRKMRKRMM NA 42 SEQ ID No. 48 NA LRWLRWRLLLRWLRWRLL NA 45 SEQ ID No. 49 NA LWKLWKWLLLWKLWKWLL NA 46 SEQ ID No. 50 NA LYKLYKYLLLYKLYKYLL NA 47 SEQ ID No. 51 NA LQKLQKQLLLQKLQKQLL NA - Similar experiments to those described in Example 2 were conducted to test the efficacy of the peptides according to the invention against HIV infection.
- The glioma cell line NP2 over-expressing both CD4 and the appropriate co-receptor (CCR5 or CXCR4) were maintained in DMEM supplemented with 10% FCS. 2×104 cells were plated per well of a 48-well plate 24 h prior to infection and grown at 37 C. The cells were then washed, and incubated in DMEM/FCS containing peptide concentrations ranging from 0.1 to 10 micromolar, at 37 C for 30 minutes. 200 focus-forming units of HIV-1 stocks were then added to each well, and the cells incubated at 37 C for a further 2 hours. The cells were then washed twice in PBS and fresh medium replaced. After 3 day's growth the cells were fixed in cold methanol:acetone, and stained in situ for expression of HIV-1 p24 using a monoclonal anti-p24 followed by a secondary anti-mouse beta-galactosidase conjugate. Expression was visualised by X-Gal staining and infectious foci enumerated by light-microscopy.
- It was found that peptides according to the invention had similar efficacy against HSV-1 and HIV.
-
FIG. 8 illustrates the anti-HIV action ofpeptide GIN 7 against HIV isolate SF162, grown in NP-2 glioma cells overexpressing CCR5 co-receptors. - Similar data was generated for other HIV strains, and in other host cells types. Notably
GIN 1p (apoEdp) had no detectable anti-HIV activity in the one combination of HIV strain and cell type against which this peptide was tested, and at the concentrations used here (up to 10 μM). This would suggest the W substituted peptides according to the present invention are more potent against HIV thanGIN 1p (apoE141-149dp). - Further experiments were conducted to test the efficacy of peptides according to the present invention against HSV1.
- The methods employed were as described in Examples 1-4 expect peptides were prepared as 400 μM stocks in phosphate buffered saline (PBS).
- Experiments were conducted to investigate the effect of full substitution of L residues in the apoE141-149 tandem repeat with a single amino acid. Table 7 illustrates that peptides according to the present invention have efficacy for inhibiting the growth of HSV1 (i.e. W, R or K substitution). The peptides according to the first aspect of the invention surprisingly have more efficacy than the apoE tandem repeat (
GIN 1/MU 10). - It is interesting to note that substitution with M, Y, F, I, Q, H or N had some efficacy (comparable with the apoE tandem repeat) and as such further substitutions according to the invention may comprise these amino acids.
- Substitutions with E, A, D, S, V, T, G or P resulted in antiviral activity being abolished.
- Although the inventors do not wish to be bound by any hypothesis they have noted that substitution with amino acids with small side chains tends to abolish antiviral activity whereas as amino acids with larger side chains maintain the antiviral effects. However substitution of L with amino acids as defined by the first aspect of the invention confers surprising antiviral activity.
-
TABLE 7 SEQ HSV1 IC50 Peptide Code ID No. Sequence (μM) MU 1(GIN 6) 67 ERKERKREEERKERKREE NA MU 2 (GIN 39) 68 ARKARKRAAARKARKRAA NA MU 3 69 DRKDRKRDDDRKDRKRDD NA MU 4 (GIN 7) 3 WRKWRKRWWWRKWRKRWW 3.5 MU 5 (GIN 40) 70 MRKMRKRMMMRKMRKRMM >30 MU 6 (GIN 41) 6 YRKYRKRYYYRKYRKRYY >30 MU 771 FRKFRKRFFFRKFRKRFF >30 MU 872 IRKIRKRIIIRKIRKRII >30 MU 973 QRKQRKRQQQRKQRKRQQ >30 MU 10 ( GIN 1p)2. LRKLRKRLLLRKLRKRLL 30 MU 10 (GIN 1) 2. LRKLRKRLLLRKLRKRLL 16.5 (no N/C protect) MU 1174 NRKNRKRNNNRKNRKRNN 27.5 MU 13 75 SRKSRKRSSSRKSRKRSS NA MU 14 76 VRKVRKRVVVRKVRKRVV NA MU 15 77 TRKTRKRTTTRKTRKRTT NA MU 16 64 RRKRRKRRRRRKRRKRRR 7.5 MU 17 78 GRKGRKRGGGRKGRKRGG NA MU 18 65 KRKKRKRKKKRKKRKRKK 7.5 MU 19 79 HRKHRKRHHHRKHRKRHH NA MU 20 80 PRKPRKRPPPRKPRKRPP NA
5.2.2 Testing of Further apoE Derived Peptides. - The inventor constructed an expanded library of peptides to evaluate what apoE peptide derivatives may have antiviral activity.
- Table 8 illustrates that a number of peptides, which were based on SEQ ID No. 2 but fall outside the definition of peptides according to the first aspect of the invention, had no or poor antiviral activity (e.g. MU 24-46). It is interesting to note that MU 43 and MU 44 correspond to tandem repeats of the murine and bovine equivalents to apoE141-149 respectively whereas MU 46 corresponds to apoE141-149 (SEQ ID No. 1).
- The data presented in Table 8 for MU 58-117 demonstrate that each of these peptides, which are peptides according to the present invention have good antiviral activity which is surprisingly superior to that of apoE141-149 dp (SEQ ID No. 2)
-
TABLE 8 Peptide HSV1 IC50 Code SEQ ID No. Sequence (μM) MU 24 81 LLRKRLKRLLLRKRLKRL 40 MU 38 82 LRRLRRRLLLRRLRRRLL >30 MU 39 83 LKKLKKKLLLKKLKKKLL 30 MU 4084 LHHLHHHLLLHHLHHHLL NA MU 41 85 LDDLDDDLLLDDLDDDLL NA MU 42 86 LEELEEELLLEELEEELL NA MU 43 87 MRKLRKRLMMRKLRKRLM NA MU 44 88 LRKLPKRLLLRKLPKRLL >30 MU 45 89 WRKWRKRWW NA MU 46 1 LRKLRKRLL NA MU 58 52 WRKWRKRWWRKWRKRWW 4.25 MU 59 53 WRKWRKRWRKWRKRW 9.75 MU 60 54 WRKWRKRWWFRKWRKRWW 4 MU 61 55 WRKWRKRFFWRKWRKRFF 4.75 MU 68 56 WRKCRKRCWWRKCRKRCW 4.25 MU 83 66 WRKWRKRWWRWRKWRKRW 2.5 WR MU 111 57 LRKLRKRLLWRKWRKRWW 12.5 MU 112 58 LRKLRKRLLLRKLRKRWW >20 MU 113 59 LRKLRKRLLWRKWRKRLL 18.5 MU 114 60 WRKWRKRLLLRKLRKRLL 16 MU 115 61 WRKLRKRLLLRKLRKRLL 17.5 MU 116 62 WRKWRKFFFRKWRKRWW 3.3 MU 117 63 WRKWRKRWWFRKFRKRFF 3.3 - Further experiments were conducted to test the efficacy of peptides according to the present invention against HSV2.
- Plaque assays were performed. The methodology was as described in previous Examples for HSV1 plaque assays (including usage of Vero cells) except HSV2 clinical isolates (provided by Prof. Anthony Hart of Liverpool University) were employed instead.
- A number of peptides that were found to have efficacy against HSV1 were also tested against HSV2. Table 9 illustrates that peptides according to the present invention were effective against both HSV1 and HSV2. This illustrates that the peptides will have broad spectrum activity against viruses.
-
TABLE 9 SEQ ID HSV2 IC50 Peptide code No. Sequence (μM) GIN 345 WRKWRKRWWLRKLRKRLL <3.3 GIN 324 WRKWRKRWRKWRKR 6.25 MU 4 (GIN 7) 3 WRKWRKRWWWRKWRKRWW <3.3 MU 59 53 WRKWRKRWRKWRKRW 10 MU 83 66 WRKWRKRWWRWRKWRKRWWR <3.3 MU 111 57 LRKLRKRLLWRKWRKRWW 6.5 MU 112 58 LRKLRKRLLLRKLRKRWW 16 MU 113 59 LRKLRKRLLWRKWRKRLL 11.75 MU 114 60 WRKWRKRLLLRKLRKRLL 9 - Further experiments were conducted to test the efficacy of peptides according to the present invention against Human Immunodeficiency Virus (HIV). The effect of a peptide according to the present invention was tested against a different HIV strain to that tested in Example 4.
- Peptides (prepared as described previously) were diluted in 50 μl aliquots and mixed with T-cells (C8166) at 40,000 cells per well. Next HIV-1 111B was added at a multiplicity of infection (MOI) of 0.01, and the mixture incubated for 5 days at 37° C. Syncytia formation was assessed visually using an inverting microscope, and viral gp120 levels in supernatants assessed by a gp120 ELISA using GNA for antigen capture. 96-well plates coated with 50 ul GNA (Galanthus nivalis) were washed, then treated with 100 μl RPMI (10% foetal calf serum) and left for one hour. After further washing, 25 μl test sample supernatants were added to wells, along with dilutions of infected control samples. After lysis by 3 hr treatment with 0.5% Empigen (detergent used to lyse virus) to all wells, and washing, 50 μl of human anti-HIV sera was added, and plates incubated overnight. After further washing, 50 μl of a 1000× dilution of anti-human Ig peroxidase conjugate was added, and plates incubated at 37° C. for 90 min. After a final wash, 50 μl peroxidase substrate was added to each well, and plates incubated for 10-30 min. Reaction was stopped with 25 μl 2M H2SO4, and A450 measured.
- Further tests were conducted to support the data presented in Example 4 illustrating that peptides according to the present invention were effective against HIV as well as both HSV1 and HSV2.
- GIN 32 (SEQ ID No. 4) had an IC50 of 7.5 μM for inhibiting HIV-1 growth. The efficacy of this was similar in HSV1, HSV2 and HIV. This confirms that peptides according to the present invention have broad antiviral effects.
Claims (22)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/702,919 US20100221273A1 (en) | 2003-12-17 | 2010-02-09 | Treatment of viral infections |
US13/550,029 US20130150288A1 (en) | 2003-12-17 | 2012-07-16 | Treatment of viral infections |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0329254.7A GB0329254D0 (en) | 2003-12-17 | 2003-12-17 | Treatment of viral infections |
GB0329254.7 | 2003-12-17 | ||
US10/580,761 US7691382B2 (en) | 2003-12-17 | 2004-12-17 | Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
PCT/GB2004/005360 WO2005058959A2 (en) | 2003-12-17 | 2004-12-17 | Treatment of viral infections |
US12/702,919 US20100221273A1 (en) | 2003-12-17 | 2010-02-09 | Treatment of viral infections |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/005360 Continuation WO2005058959A2 (en) | 2003-12-17 | 2004-12-17 | Treatment of viral infections |
US11/580,761 Continuation US7640471B2 (en) | 2006-10-13 | 2006-10-13 | On-board FIFO memory module for high speed digital sourcing and capture to/from DUT (device under test) using a clock from DUT |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/550,029 Continuation US20130150288A1 (en) | 2003-12-17 | 2012-07-16 | Treatment of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100221273A1 true US20100221273A1 (en) | 2010-09-02 |
Family
ID=30471239
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/580,761 Active 2026-02-18 US7691382B2 (en) | 2003-12-17 | 2004-12-17 | Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
US12/702,919 Abandoned US20100221273A1 (en) | 2003-12-17 | 2010-02-09 | Treatment of viral infections |
US13/550,029 Abandoned US20130150288A1 (en) | 2003-12-17 | 2012-07-16 | Treatment of viral infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/580,761 Active 2026-02-18 US7691382B2 (en) | 2003-12-17 | 2004-12-17 | Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/550,029 Abandoned US20130150288A1 (en) | 2003-12-17 | 2012-07-16 | Treatment of viral infections |
Country Status (11)
Country | Link |
---|---|
US (3) | US7691382B2 (en) |
EP (2) | EP1709075B9 (en) |
JP (2) | JP2007535910A (en) |
CN (2) | CN102336815A (en) |
AU (1) | AU2004299343B8 (en) |
CA (1) | CA2548585A1 (en) |
DK (1) | DK1709075T3 (en) |
ES (1) | ES2389078T3 (en) |
GB (1) | GB0329254D0 (en) |
PL (1) | PL1709075T3 (en) |
WO (1) | WO2005058959A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080207508A1 (en) * | 2005-06-28 | 2008-08-28 | Ai2 Limited | Treatment of Fungal and/or Protist Infections |
US20090048171A1 (en) * | 2003-12-24 | 2009-02-19 | Curtis Dobson | Treatment of viral infections |
US20090169598A1 (en) * | 2004-02-27 | 2009-07-02 | A12 Limited | Treatment of bacterial infections |
US9234026B2 (en) | 2011-07-21 | 2016-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Apolipoprotein E polypeptides and their use |
WO2020223581A1 (en) * | 2019-04-30 | 2020-11-05 | Maxwell Biosciences, Inc. | Halogenated antimicrobial peptoids |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0329254D0 (en) * | 2003-12-17 | 2004-01-21 | Univ Manchester | Treatment of viral infections |
WO2007030930A1 (en) | 2005-09-13 | 2007-03-22 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
PL2085774T3 (en) * | 2008-02-01 | 2018-08-31 | Kraft Foods R & D, Inc. | Method for determining the texture of food material |
WO2009102715A2 (en) * | 2008-02-11 | 2009-08-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Peptide therapy for ocular herpes infections |
CN102816234A (en) * | 2008-02-14 | 2012-12-12 | 国立大学法人京都工艺纤维大学 | Peptide, use of the peptide, method for production of the peptide, solid phase having the peptide immobilized thereon, and method for production of the solid phase |
CA2928846A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
US20120053128A1 (en) * | 2010-08-26 | 2012-03-01 | Xavier University | Method of inhibiting angiogenesis |
CN104159611A (en) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
WO2013148305A1 (en) * | 2012-03-29 | 2013-10-03 | Xavier University Of Louisiana | Method for treating diabetic retinopathy |
CA2962951A1 (en) * | 2014-10-01 | 2016-04-07 | Plant Health Care, Inc. | Hypersensitive response elicitor peptides and use thereof |
WO2016054342A1 (en) | 2014-10-01 | 2016-04-07 | Plant Health Care, Inc. | Elicitor peptides having disrupted hypersensitive response box and use thereof |
WO2016054250A1 (en) * | 2014-10-01 | 2016-04-07 | Cascadia Life Sciences Llc | Anti-viral peptides |
BR112018069945A2 (en) | 2016-04-06 | 2019-02-05 | Plant Health Care Inc | beneficial microbes for the distribution of peptides or effector proteins and their use |
US10793608B2 (en) | 2016-04-06 | 2020-10-06 | Plant Health Care, Inc. | Hypersensitive response elicitor-derived peptides and use thereof |
CN116813712B (en) * | 2023-06-16 | 2024-03-29 | 东北农业大学 | Antibacterial peptide W33 with alpha-helical structure and rich in Trp, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164789A1 (en) * | 1998-03-11 | 2002-11-07 | Laskowitz Daniel T. | Methods of suppressing microglial activation |
US7691382B2 (en) * | 2003-12-17 | 2010-04-06 | Ai2 Limited | Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5473039A (en) * | 1989-08-18 | 1995-12-05 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs |
WO1993000443A1 (en) * | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
US5344822A (en) | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
AU9676598A (en) * | 1997-09-30 | 1999-04-23 | Duke University | Apolipoprotein e/growth factor complexes and methods of use |
GB0200757D0 (en) * | 2002-01-15 | 2002-02-27 | Univ Manchester | Diagnostic methods |
-
2003
- 2003-12-17 GB GBGB0329254.7A patent/GB0329254D0/en not_active Ceased
-
2004
- 2004-12-17 US US10/580,761 patent/US7691382B2/en active Active
- 2004-12-17 EP EP04806160A patent/EP1709075B9/en not_active Not-in-force
- 2004-12-17 EP EP10010764A patent/EP2277911A1/en not_active Withdrawn
- 2004-12-17 DK DK04806160.0T patent/DK1709075T3/en active
- 2004-12-17 JP JP2006544559A patent/JP2007535910A/en active Pending
- 2004-12-17 CN CN2011102495236A patent/CN102336815A/en active Pending
- 2004-12-17 AU AU2004299343A patent/AU2004299343B8/en not_active Ceased
- 2004-12-17 CA CA002548585A patent/CA2548585A1/en not_active Abandoned
- 2004-12-17 ES ES04806160T patent/ES2389078T3/en active Active
- 2004-12-17 CN CN2004800379084A patent/CN1894281B/en not_active Expired - Fee Related
- 2004-12-17 PL PL04806160T patent/PL1709075T3/en unknown
- 2004-12-17 WO PCT/GB2004/005360 patent/WO2005058959A2/en active Application Filing
-
2010
- 2010-02-09 US US12/702,919 patent/US20100221273A1/en not_active Abandoned
-
2012
- 2012-02-02 JP JP2012020504A patent/JP2012115277A/en active Pending
- 2012-07-16 US US13/550,029 patent/US20130150288A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164789A1 (en) * | 1998-03-11 | 2002-11-07 | Laskowitz Daniel T. | Methods of suppressing microglial activation |
US7691382B2 (en) * | 2003-12-17 | 2010-04-06 | Ai2 Limited | Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
Non-Patent Citations (1)
Title |
---|
Hamy et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. PNAS April 15, 1997 vol. 94, no. 8: 3548-3553. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090048171A1 (en) * | 2003-12-24 | 2009-02-19 | Curtis Dobson | Treatment of viral infections |
US8017579B2 (en) | 2003-12-24 | 2011-09-13 | Ai2 Limited | Treatment of viral infections |
US20090169598A1 (en) * | 2004-02-27 | 2009-07-02 | A12 Limited | Treatment of bacterial infections |
US8524861B2 (en) | 2004-02-27 | 2013-09-03 | Ai2 Limited | Treatment of bacterial infections |
US20080207508A1 (en) * | 2005-06-28 | 2008-08-28 | Ai2 Limited | Treatment of Fungal and/or Protist Infections |
US8916516B2 (en) | 2005-06-28 | 2014-12-23 | Ai2 Limited | Treatment of fungal and/or protist infections |
US9234026B2 (en) | 2011-07-21 | 2016-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Apolipoprotein E polypeptides and their use |
US10125184B2 (en) | 2011-07-21 | 2018-11-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Apolipoprotein E polypeptides and their use |
WO2020223581A1 (en) * | 2019-04-30 | 2020-11-05 | Maxwell Biosciences, Inc. | Halogenated antimicrobial peptoids |
Also Published As
Publication number | Publication date |
---|---|
CA2548585A1 (en) | 2005-06-30 |
JP2007535910A (en) | 2007-12-13 |
EP2277911A1 (en) | 2011-01-26 |
EP1709075A2 (en) | 2006-10-11 |
CN102336815A (en) | 2012-02-01 |
ES2389078T3 (en) | 2012-10-23 |
WO2005058959A2 (en) | 2005-06-30 |
US7691382B2 (en) | 2010-04-06 |
CN1894281A (en) | 2007-01-10 |
JP2012115277A (en) | 2012-06-21 |
EP1709075B9 (en) | 2012-10-24 |
AU2004299343B2 (en) | 2011-03-10 |
PL1709075T3 (en) | 2012-11-30 |
DK1709075T3 (en) | 2012-08-27 |
US20130150288A1 (en) | 2013-06-13 |
AU2004299343A1 (en) | 2005-06-30 |
WO2005058959A3 (en) | 2005-12-15 |
GB0329254D0 (en) | 2004-01-21 |
EP1709075B1 (en) | 2012-06-06 |
AU2004299343B8 (en) | 2012-02-23 |
US20070117746A1 (en) | 2007-05-24 |
CN1894281B (en) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100221273A1 (en) | Treatment of viral infections | |
EP4414377A1 (en) | Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof | |
US8017579B2 (en) | Treatment of viral infections | |
US5441936A (en) | Antiviral peptides | |
WO2009155789A1 (en) | Polypeptides and derivatives thereof that inhibit hiv infection | |
Vangelista et al. | Critical role of the N-loop and β1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity | |
US9233138B2 (en) | Compositions for promoting HIV-1 virolysis and methods using same | |
NO315546B1 (en) | Inhibition of retroviral infection | |
KR100438415B1 (en) | Novel antiviral peptide derived from Helicobacter pylori and use thereof | |
US7754687B2 (en) | Methods of inhibiting viral infection | |
EP4293037A1 (en) | Artificial small molecule interfering peptide of dapk1 phosphorylated substrate and pharmaceutical use thereof | |
US5578573A (en) | Viral integrase inhibiting peptides | |
KR20240137685A (en) | Method for optimizing broad-spectrum anti-coronavirus lipopeptides that are viral membrane fusion inhibitors and their uses | |
KR100517055B1 (en) | Peptides with increased hydrophobicity by substituting one or more amino acids of Pep-27 peptide and pharmaceutical compositions containing thereof | |
Woo et al. | Characterization of Rhodamine Conjugated Agiotensin II Peptide: Synthesis, Analysis and Receptor Binding and Internalization. | |
WO2012101617A1 (en) | Antiviral peptides | |
WO2012101614A1 (en) | Antiviral peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AI2 LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE UNIVERSITY OF MANCHESTER;REEL/FRAME:023923/0173 Effective date: 20060615 Owner name: THE UNIVERSITY OF MANCHESTER, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOBSON, CURTIS;REEL/FRAME:023922/0621 Effective date: 20050221 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: SCHLUMBERGER TECHNOLOGY CORPORATION, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VARKEY, JOSEPH;YUN, JUSHIK;UNAL, BURCU;REEL/FRAME:029995/0691 Effective date: 20130220 |